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ABSTRACT 
 
Cardiovascular disease is a leading contributor to mortality the world over, affecting 
millions of people each year.  This, combined with its associated monetary and 
societal costs, has made the investigation of the etiology and pathophysiology of CVD 
a scientific priority.  Researchers have developed numerous tools to aid in these 
studies, many of which have been successful in developing effective clinical therapies.  
However, while technical and medical advances have helped slow the spread of this 
burgeoning epidemic, CVD-related deaths are still on the rise globally.  It is for this 
reason that the doctoral thesis presented here aims to develop a better 
understanding of the pathogenesis of CVD and to determine the magnitude of cardiac 
regenerative potential.  
 
In PAPER	 I we present clear methods for the isolation, culture, and functional 
characterization of adult murine cardiomyocytes for in vitro studies.  We show that 
our method results in a single-cell suspension of electrochemically active, rod-shaped 
adult cardiomyocytes that maintain calcium sensitivity and contractile function.  We 
further present proper cell culture conditions, optimized methods for whole-cell 
patch clamp and adenovirus-mediated gene delivery, as well as a clear protocol for 
the collection and analysis of contractility traces and calcium transients. 
 
In PAPER	 II	we identify estrogen-related receptor β (ESRRβ) as a causative factor in 
the pathogenesis of dilated cardiomyopathy (DCM).  We show that mice lacking 
ESRRβ develop DCM in mid-life and die prematurely. We further show that human 
myocardial tissue samples from DCM patients lack the expected nuclear ESRRβ 
localization, suggesting a role for ESRRβ also in human disease onset.  
 
In PAPER	III we describe the role of SGK1 in the development of the fatal ventricular 
arrhythmias commonly associated with heart failure.  Using transgenic mice 
expressing either constitutively active or dominant negative forms of SGK1, we show 
that chronic SGK1 activation in disease results in fatal ventricular arrhythmias due to 
an increased persistent sodium current, INaL, leading to prolonged action potential 
duration.  We further show a direct interaction between SGK1 and the primary 
cardiac voltage-gated sodium channel, Nav1.5, and have identified putative 
phosphorylation sites contained in the SCN5a gene.  Together, these findings suggest 
direct SGK1 regulation of sodium channel kinetics and gating. 
 
In PAPER	 IV we compare transcriptional profiles from three zebrafish models of 
cardiac regeneration to determine common genetic drivers of the regenerative 
response.  By comparing the transcriptional profile of our genetic cardiomyocyte 
ablation model to those of two apical resection models and one cryoablation model, 
we have identified 16 genes to be up-regulated in all screens and 1 gene down-
regulated.  Gene ontology analysis of this gene set reveals significant enrichment in 
biological processes associated with the cell cycle and mitosis, and pathway analysis 
has provided a list of putative upstream regulators of these genes.  Further analysis of 
all transcription profiles also indicated a large number of model-specific genes, 
indicating that these disease models, and thus the regenerative responses activated 
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therein, should not be considered interchangeably, but should be regarded as 
genetically distinct models of cardiac regeneration. 
 
Finally, in PAPER	V	we use 14C dating to determine the magnitude and dynamics of 
human cardiac cell turnover in dilated cardiomyopathy.  The amount of 14C contained 
in postmortem cardiac tissue from patients diagnosed with DCM was compared to 
atmospheric levels at the time of the patient’s birth to determine the rate of cardiac 
cell turnover.  Our mathematical model predicts that cardiomyocyte turnover is at 
least maintained in DCM.  Importantly, though we report a significant increase in 
cardiomyocyte ploidy with disease onset, this was not sufficient to entirely account 
for the increased 14C concentration. 
 
Together, this work provides valuable information regarding the pathogenesis of both 
DCM and arrhythmogenic heart failure, and contributes to the growing literature 
surrounding potential regenerative therapies for cardiovascular disease.  
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Cardiovascular Disease – 
An Epidemic 
 
 											
1 Cardiovascular Disease – An Epidemic 
 
The epidemic of non-communicable diseases, in the midst of which we currently find 
ourselves, is the most widespread and longest-standing human epidemic the world 
has ever seen.  It has been apparent to researchers and clinicians for some time that, 
of these diseases, the primary contributors to the global health burden are 
cardiovascular diseases (CVDs).  However, it was not until 2011 that the global heads 
of state joined at the United Nations to discuss this issue with a focus on prevention.   
It was clear then, as it was in 2001 with the snowballing HIV/AIDS epidemic, that CVDs 
do not only present a substantial global health burden, but have also affected the 
global economy, and in many countries have contributed to the widening of 
socioeconomic gaps and the reinforcement of disparate socioeconomic classes. 
 
In this chapter I will discuss the current state of cardiovascular disease across the 
globe and the measures being taken to decrease its prevalence.  I will then discuss the 
economic burden of cardiovascular disease, and conclude with a discussion of 
cardiovascular disease from a sociological perspective.   
 
1.1 Cardiovascular Disease as a Global Health Concern 	
In 2013 the UN announced targets for reducing mortality due to non-communicable 
disease by 2025.  These targets involve a reduction of several behavioral and 
biological risk factors including: harmful alcohol use, physical inactivity, salt/sodium 
intake, tobacco use, high blood pressure, and obesity/diabetes.  By reducing the 
prevalence of these risk factors they would like to achieve a 25% reduction of all-
cause premature CVD mortality by 2025.  It is estimated that if current trends in 
diabetes mellitus, tobacco use, changes in blood pressure, and obesity continue, the 
1 
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number of premature CVD deaths will rise from 5.9 million (in 2013 when the study 
was conducted) to 7.8 million by 2025 [4].  For comparison consider that, according 
to the World Health Organization, in 2015 1.1 million people died from HIV/AIDS, 1.4 
million people died from tuberculosis, 1.25 million people died on the world’s roads, 
and approximately 800,000 deaths were self-inflicted.  If unchecked, the premature 
CVD mortality in 2025 could be greater than all of these figures combined. 
Of the targets studied, the prevalence of hypertension showed the greatest influence 
on the premature CVD mortalities in 15 and 16 of the 21 regions studied for men and 
women respectively, though it must be said that estimates differed strikingly with 
geographical region [4].  Notable exceptions were women in tropical Latin America, 
men in high-income Asia Pacific, and both men and women in Australasia and high-
income North America, where halting obesity had the greatest impact.  Additionally, 
smoking was the leading risk factor scenario for men in Central Asia, Central Sub-
Saharan Africa, North Africa and the Middle East, and for women in high-income Asia 
Pacific and Western Europe.  Interestingly, a reduction in obesity had the second 
largest impact on premature CVD mortality for women, while a reduction in tobacco 
smoking was the second-largest determinant for men [4].               
Overall, the combined scenario in which all of the risk factor targets are achieved in 
2025 does have the potential to decrease global CVD deaths to an estimated 5.7 
million.  However, perhaps understandably, the change in risk varies widely across 
regions.  This is to say that while this global health crisis may be somewhat mitigated 
for certain privileged populations, the gains will not be distributed equally.  For 
higher-income regions already experiencing rapid declines in CVD mortality, the 
current UN targets may not even be stringent enough to yield any measurable 
benefits, while in some middle- and lower-income regions a 25% reduction in CVD 
mortality is only achievable when all of the targets are reached.  Thus, if this epidemic 
is to be curbed universally, it is clear that global healthcare disparities will need to be 
addressed, and investments in CVD prevention, treatment, research, and education 
will need to be expanded beyond western society. 
  
1.2 Cardiovascular Disease as an Economic Burden 
 
Cardiovascular disease is not only the world’s most prevalent killer, but also the most 
costly.  In a policy statement from the American Heart Association, researchers 
calculated projections for CVD prevalence between 2010 and 2030 and the resultant 
direct and indirect medical costs [5].   
 
The primary cause for the increased prevalence of CVD in the United States is the 
aging population.  People 65 years or older – especially those over 80 years of age – 
show a higher prevalence for all CVD, and with the near exponential advances in 
medical technology and end-of-life care, this population is expected to grow 
significantly over the next two decades.  This growth translates to an additional 3 
million people with heart failure, 8 million people with coronary heart disease, 4 
million people with stroke, and a devastating 27 million people diagnosed with 
hypertension by 2030.  Overall, the authors project that by 2030, 40.5% of the US 
population will have some form of CVD, and between 2010 and 2030 the direct 
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medical costs associated with these diseases are expected to triple, from $272.5 
billion to $818.1 billion.  Indirect costs are expected to increase by 61% between 2010 
and 2030, from $171.7 billion to $275.8 billion.  Together, these increases amount to 
a projected total cost of CVD exceeding $1 trillion by 2030 [5].      
 
The projected economic burden associated with CVD does not however have to be as 
debilitating as the disease itself.  Because CVD is largely preventable, decreasing its 
prevalence will in turn decrease its economic impact.  The projections presented 
assume no change in preventative health-care measures and a linear increase in risk 
over time. It stands to reason that focusing on improving population-level risk factors 
will result in a significant decline in CVD prevalence and its economic impact in turn.  
Medical research is one clear way to help decrease the burden of CVD, by helping to 
develop more effective treatments for those afflicted, but widespread educational 
programs and equitable access to CVD specialists and services will also be necessary 
to ensure that everyone, regardless of socioeconomic status, receives the knowledge 
and healthcare they require and deserve.         
 
1.3 The Socioeconomic Implications of Cardiovascular Disease    
 
The inequalities currently associated with cardiovascular healthcare represent a 
persistent public health concern that is not exclusive to developing nations.  Even in 
the most affluent nations the risk of developing coronary disease is unevenly 
stratified across socioeconomic classes, with socioeconomic depravation serving as a 
powerful independent predictor of HF development. As such, understanding the 
relationship between socioeconomic status (SES), the onset of CVD, and its eventual 
progression to heart failure may help policymakers develop more equitable and 
effective prevention, diagnosis, and treatment strategies.   
 
Socioeconomic position can be assessed by numerous measures, the importance of 
each varying over the course of one’s life.  They may be characterized broadly as 
education, employment relations, occupation, income, social class, total assets, 
housing characteristics, area level measures, and composite indicators [6].  The most 
frequently applied composite area level indicator in HF research is the Carstairs 
deprivation index, which assigns individuals a score based on residence postcodes.   
Scores range from 1 (least deprived) to 5 (most deprived).  There have been nine 
studies reporting an increased incidence of HF associated with lower SES.  Two 
studies have compared high vs. low income.  In Malmö, Sweden the risk of HF 
hospitalization is 45% lower for individuals with an annual income >250,000 Swedish 
Kronor as compared to individuals whose income was <50,000 Swedish Kronor [7].  
Similarly, in Denmark the incidence of HF is 34% and 33% lower for high-income men 
and women respectively [8].  Similar results were attained when education level was 
substituted for income as the primary SES indicator and, perhaps most remarkably, 
education alone was independently associated with reduced ejection fraction and left 
ventricular dilation.  The remaining seven reports compare levels of deprivation and 
illustrate, using different primary measures, that the adjusted risk of developing HF is 
~30-50% higher with greater deprivation [9-15].  
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SES also associates with overall morbidity and mortality.  Age-standardized rates of HF 
hospitalization climb incrementally across income deciles [6], and an investigation of 
the elderly participants in the Longitudinal Study on Aging shows that an eighth grade 
education or less is significantly associated with a primary discharge diagnosis of HF 
[16, 17].  Socioeconomically deprived patients hospitalized with heart failure are at 
higher risk for readmission, and low neighborhood median household income confers 
a greater risk of all-cause re-hospitalization.  Furthermore, the relationship between 
SES and hospitalization is echoed in figures of mortality; the more deprived, the lower 
the survival.  In the Medicare cohort, low and lower-middle class patients had higher 
1-year mortality than higher-class subjects, and participants in the Atherosclerosis 
Risk in Communities study with a high co-morbidity burden, and living in low-income 
areas also experienced an increased risk of death [10].  It is interesting then that, 
despite the vast literature illustrating the variation in HF morbidity and mortality 
across socioeconomic strata, there is a paucity of evidence supporting equitable 
treatment. 
 
It is, however, clear from these studies that socioeconomic deprivation is a powerful 
indicator of cardiac pathogenesis.  The pathways mediating these inequalities can be 
modulated by both public health and clinical interventions, but only through 
concerted, interdisciplinary efforts will we be able to attenuate these unacceptable 
and unequivocal inequalities.  By learning as much as we can about how to combat 
this growing epidemic, we will ensure that the proper care be administered to any 
and everyone who needs it.             
		 5	
 
 
The Healthy Heart 	
2 The Healthy Heart 
 
 	
Figure	 1:	 A	 schematic	 of	 the	 adult	 human	 heart.	 Blue	 and	 red	 areas	 represent	 the	 flow	 of	
deoxygenated	and	oxygenated	blood,	respectively.		Image	adapted	from	[18].	
 
Cardiac dysfunction occurs when the heart, for any reason, is unable to meet the 
physical demands placed upon it and is therefore unable to supply oxygen to the 
systemic circuit or to itself.  There are myriad known causes for heart disease, often 
with interrelated pathogeneses, but in order to fully characterize the pathological 
mechanisms governing these various conditions, and to determine salient therapeutic 
strategies, it is first necessary to understand normal heart structure and function. 
 
In this chapter I will outline the basic structure and function of the normal human 
heart, define the common physiological and diagnostic parameters, and provide a 
brief summary of the regulation of normal human circulation.  
 
 
 
 
 
2 
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2.1 Normal Cardiac Function 
 
The adult human heart consists of four chambers whose primary function is to pump 
deoxygenated blood to the lungs and oxygenated blood throughout the rest of the 
body.  The two atria, the right atrium (RA) and the left atrium (LA) are composed of 
two thin, orthogonal, overlaying muscular sheaths and serve both as reservoirs and 
pumps for deoxygenated (RA) and oxygenated (LA) blood.  The two ventricles, the 
right ventricle (RV) and the left ventricle (LV), are composed of much thicker muscle 
walls and are tasked with pumping blood from the low-pressure venous systems to 
the higher-pressure arterial systems (Figure	1).  
 
The right atrium is the first to receive the body’s deoxygenated blood.  Deoxygenated 
blood from the upper and lower limbs enters through the superior and inferior vena 
cava, respectively, and deoxygenated blood from the heart itself enters through the 
coronary sinus.  The right ventricle then receives the deoxygenated blood from the 
right atrium through the right atrioventricular (tricuspid) valve at 0 pressure, and 
pumps the blood through the pulmonary artery to the lungs at a peak systolic 
pressure of ~25 mmHg.  The blood is oxygenated in the lungs via diffusion and returns 
to the left atrium through the pulmonary veins.  The left ventricle receives the newly 
oxygenated blood from the left atrium via the left atrioventricular (mitral) valve, also 
at 0 pressure, and pumps this blood into the aorta and systemic circuit at a peak 
pressure of ~120 mmHg.  Both ventricles eject similar volumes of blood at the same 
rate (heart rate).  Therefore, since the left ventricle has a much higher ejection 
pressure, it performs approximately 5 to 7 times more pressure work than the right 
ventricle.  It is for this reason that most cardiomyopathies stem from left ventricular 
dysfunction, and why most therapies focus on increasing left ventricular functionality 
[19].  
 
2.2 The Cardiac Cycle 
 
At rest, the heart beats at a rate of approximately 70-75 beats per minute (bpm).  
Normal, non-stenotic valves offer zero resistance and open as a function of the 
pressure differential across the valve.  At a heart rate of 75 bpm, a complete filling 
and emptying cycle takes 0.8 seconds and consists of two primary phases: systole and 
diastole [19].  The cardiac cycles are analogous between the two sides of the heart, 
the primary differences pertaining only to the lower pressures maintained in the right 
ventricle and pulmonary artery.  For the sake of simplicity, the following discussion 
will use the left heart as an example.   
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Figure	 2:	 Pressure	 and	 volume	 curves	 depicting	 the	 cardiac	 cycle.	 	 Aortic	 and	 atrial	 pressures	 are	
superimposed	on	ventricular	pressure	curves.	 	Ventricular	volume	is	depicted	 in	red,	and	below	is	a	
corresponding	 electrocardiogram.	 	 The	 phonocardiogram	 depicts	 the	 1st,	 2nd,	 and	 slight	 3rd	 heart	
sounds	during	systole	and	diastole.	Image	adapted	from	[20]		
 
Left ventricular systole is the contractile period of the heart cycle, which can be 
subdivided into three phases: the isovolumic contraction period (ICP), the rapid 
ejection phase, and the slower ejection phase.   In the left ventricle the ICP begins 
with the closure of the mitral valve (the first heart sound) and ends with the opening 
of the aortic valve.  It is during this phase that the maximum rate of ventricular 
pressure 
!"!"  is reached, and this pressure work is used to pump blood to the aorta 
during rapid ejection.  Approximately 2/3 of the ventricular blood is emptied into the 
aorta during the rapid ejection phase, resulting in slight aortic distension and a 
decrease in aortic 
!"!" .  The slower ejection period occurs at the peak of the aortic 
pressure curve as the ventricles begin to relax, and ventricular pressure decreases 
below aortic pressure.  For a short period, even though the ventricular pressure is 
lower than the aortic pressure, blood is still able to flow into the aorta at a slow rate 
due to its inertia.  However, as the pressure differential between the aorta and the 
left ventricle increases further, a small backflow of blood closes the aortic valve (the 
second heart sound) [21].   
 
Left ventricular diastole is the relaxation and filling period of the heart cycle, 
consisting of two primary events: the isovolumic relaxation period, spanning the time 
between the closure of the aortic valve and the opening of the mitral valve, and the 
filling period, during which time blood flows into the ventricle.  During the isovolumic 
phase the ventricle relaxes, but no filling can occur until the ventricular pressure is 
low enough to allow the mitral valve to open.  Once the ventricular pressure is 
sufficiently decreased, approximately 2/3 of the ventricle is filled by passive blood 
flow from the atrium.  This occupies the first 1/3 of diastole and is called passive 
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rapid-filling.  The remaining third of the blood is then pumped into the heart by atrial 
contraction late in diastole and is called active rapid-filling.  As in systole, there is a 
short period of slower, inertial filling between these two phases, and diastole ends 
with the closure of the mitral valve prompting a new ventricular contraction and a 
new cardiac cycle [21] (Figure	2).   
 
Normal end diastolic volume (EDV) is ~120 mL, and normal end systolic volume (ESV) 
is ~40 mL.  This equates to a normal stroke volume (SV) of ~80 mL (EDV-ESV).  Stroke 
volume thus describes the total volume of blood pumped into the systemic 
vasculature during systolic contraction.  This parameter, however, is most often 
expressed in relation to the total end diastolic volume, giving the fraction of blood 
ejected from the heart, or the ejection fraction (EF), according to the following 
equation:  
 EF =  𝑆𝑉𝐸𝐷𝑉  × 100. 
 
A normal ejection fraction is thus ~67% (55% - 70%) with decreases likely indicating 
weakened myocardium and/or cardiac dysfunction.  Similar calculations can be 
performed using left ventricular end systolic and diastolic dimensions (LVESD, LVEDD) 
to quantify changes in ventricular morphology.  Fractional shortening (FS) is defined 
as the fraction of any diastolic dimension that is lost in systole, and is calculated as 
follows: 
 𝐹𝑆 =  (𝐿𝑉𝐸𝐷𝐷 − 𝐿𝑉𝐸𝑆𝐷)𝐿𝑉𝐸𝐷𝐷  × 100. 
 
Similar to EF, decreased FS often indicates dysfunction of the heart’s mechanical 
capability. Normal FS values range between 25-45% while values <15% are considered 
to be severe.     
 
Once oxygenated blood leaves the heart it enters the systemic vasculature through 
arteries.  Arteries carry oxygenated blood away from the heart down to arterioles and 
further to capillaries where nutrient and oxygen transfer occurs with the systemic 
tissues.  Arteries are necessarily thicker and stronger than veins, as they must 
withstand significantly higher pressures from left ventricular contractions.  
Deoxygenated blood from 
the capillaries then enters 
the veins, which carry 
blood back to the heart 
(Figure	3).  Veins constitute 
a low-pressure, large 
volume system called the 
venous capacitance 
system, which can be used 
to regulate heart rate 
during physical activity.  
Figure	 3:	 Schematic	 showing	 the	 flow	of	 oxygenated	 blood	 from	
the	heart	through	the	venous	capacitance	system.		Image	adapted	
from	[1].	
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During exercise blood is forced out of the system and returned to the right atrium by 
muscle contraction and various nervous influences.  This so-called venous return 
results in increased heart rate as atrial filling stimulates contraction.  The only 
exceptions to the artery/vein dichotomy are the pulmonary arteries and veins.  While 
they still shunt blood away from and toward the heart, because they lead to the 
lungs, the pulmonary arteries actually carry deoxygenated blood, while the 
pulmonary veins carry oxygenated blood from the lungs to the heart’s left atrium 
[19].   
 
Arterioles are the small arteries providing the major arterial resistance against which 
the left ventricle must work.  The regulation of this peripheral vascular resistance 
determines how much blood reaches the capillaries, the rate of oxygen and nutrient 
transfer, but perhaps most importantly, the arterioles serve as the main contributors 
to systemic blood pressure.  Resistance hypertension can be defined thus as an excess 
of arteriolar constriction resulting in increased overall pressure of the arterial tree.  
Many treatments for hypertension, and indeed many forms of cardiomyopathy, are 
focused on decreasing this pressure.   
 
2.3 Excitation-Contraction Coupling (ECC) 
 
Though the heart is comprised of many different cell types, the cells primarily 
responsible for cardiac contractile function are (1) the cardiac pacemaker cells, which 
produce the electrical signal for contraction, and (2) the cardiomyocytes themselves, 
which receive the signal and perform the contraction.  The cardiac pacemaker cells 
are a group of specialized cells comprising the sinoatrial (SA) node in the heart’s right 
atrium, the atrioventricular (AV) node in the right ventricle, and the Bundle of His and 
Purkinje fibers spreading throughout the heart.  These cells are capable of 
spontaneously generating action potentials (APs), and propagate the depolarization 
wave throughout the heart. In cardiac muscle, AP propagation occurs via intercellular 
ion “leakage” via gap junctions, which alters cardiomyocyte membrane potential and 
leads to cell contraction. This entire process is referred to as excitation-contraction 
coupling (ECC) [22].    
 
In its broadest use, cardiac ECC refers to the entire process by which electrical 
activation of cardiomyocytes leads to the activation of a cardiomyocyte’s contractile 
apparatus.  This includes everything from the initial membrane depolarization via the 
AP, to the activation of the Ca2+ transient, to myofilament activation in response to 
increased intracellular Ca2+ levels ([Ca2+]i).   
 
Though the process is continuous in the heart, it can be said to begin with the 
depolarization of the sarcolemma due to the propagation of the AP from the SA node.  
The AP causes depolarization of the cardiomyocyte’s sarcolemma via a large influx of 
sodium ions, primarily through the most abundant cardiac voltage-gated sodium 
channel, Nav1.5.  The resultant increased membrane potential triggers the opening of 
the voltage-gated L-type calcium channels (LTCC) allowing an inward flux of calcium 
ions (ICa).  The LTCCs, which span the t-tubular membrane, are localized in close 
proximity to the sarcoplasmic reticulum (SR), and specifically to the ryanodine 
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receptor (RyR).  The RyR is a specialized Ca2+-activated Ca2+ channel housed within the 
SR membrane.  The Ca2+ that enters the small cleft between these two channels 
activates the RyR and allows for more Ca2+ to exit the SR into the cytosol.  This 
process, termed calcium-induced calcium release (CICR), is essential to the proper 
regulation of the ECC mechanism [23, 24].   
 
The rise in [Ca2+]i causes sarcomeric contraction via myofilament activation, as Ca
2+ 
ions bind to the troponin complex found on the actin filaments in complex with 
tropomyosin.  The Ca2+ binding causes a conformational change in tropomyosin, 
exposing the myosin-binding site on the actin filament.  Using the energy stored in 
the ADP and Pi molecules found on the myosin head, myosin binds to the actin 
filament, pulls it and creates the force for contraction.  The return of ATP molecules 
to the myosin head allows for the dissociation of actin and myosin and results in 
relaxation (Figure	 4).  The sarcomeres are composed of two myosin heavy chain 
(MHC) isoforms, α and β.  Their expression is exceptionally tightly regulated with 
deviations from this ratio often indicating pathology, as will be discussed later.  
 
In the continued presence of calcium this process will repeat.  In this way, relaxation 
ultimately depends on the decline of [Ca2+]i.  Ca
2+ is primarily removed from the 
cytosol by reuptake into the SR through the SR Ca-ATPase (SERCA), which is regulated 
by phospholamban (PLB), or by being transported out of the cell via the sarcolemmal 
Na/Ca exchanger (NCX).  Mitochondrial uptake and transport out of the cell via the 
sarcolemmal Ca-ATPase also play a role [23, 24]. 
 
2.4 Nervous Regulation of Circulation 
 
Though the heart is able to function without continuous nervous activity, the 
autonomic nervous system does play an important role in modulating contractile 
activity in times of stress or increased mechanical loading.  Autonomic nervous 
control of the circulation occurs through the concerted efforts of the sympathetic and 
parasympathetic nervous system pathways.  The sympathetic pathway is governed by 
adrenergic (catecholamine) signaling and, via interaction with α- and β-adrenergic 
receptors (α-AR and β-AR), generally results in increased heart rate, cardiac output, 
and EF.  Conversely, the parasympathetic pathway is governed by cholinergic 
(acetylcholine) signaling, and generally leads to the opposite effect [25].       
 
The primary effectors of adrenergic signaling in the heart are β1- and β2-ARs. It has 
been shown that α-ARs do also have positive inotropic activity, but their most 
prominent role is in regulating peripheral resistance via the venous capacitance 
system.  In the heart both β1- and B2-AR are coupled to the stimulatory G protein, Gs.  
In the presence of β-AR agonists, conformational changes in the protein complex 
result in activation of adenylyl cyclases (AC), which convert ATP to the second 
messenger, cAMP.  The increased level of cAMP results in the activation of protein 
kinase A (PKA), which phosphorylates many proteins involved in excitation-
contraction coupling such as: LTCC, phospholamban (PLB), RyRs, and troponin I (TnI), 
resulting in increased contractility.  β1-AR appears to be coupled only to the 
stimulatory Gs pathway, while β2-AR has also been shown to couple with the 
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inhibitory Gi, which limits cAMP formation.  In this way β2-AR can contribute to a 
negative feedback system ensuring that overstimulation does not occur [25] (Figure	
4).  
 
The discovery of the essential role that β-ARs play in the control of circulation has 
lead to the therapeutic approaches widely used for heart failure treatment today.  
The first β-AR therapies were based around the concept of increasing myocardial 
contractility via inotropic agents.  The prevailing dogma was based on a simple line of 
reasoning: (1) heart failure is directly associated to poor contractility, (2) 
catecholamines are the best stimulators of myocardial contractility, and (3) 
catecholamines should thus be used to increase contractility in patients with heart 
failure.  However, at the time, the concept of β-AR desensitization had not yet been 
established, and researchers did not appreciate the high oxygen cost of increasing 
heart rate, myocardial contractility, and LV wall stress.  The β-agonist treatments 
eventually lead to fatal arrhythmias in many patients, and patients with coronary 
artery disease also showed increased incidence of myocardial ischemia.  It was later 
determined that, while acute activation of the sympathetic system is required to 
maintain homeostasis in the healthy individual, in heart failure the sympathetic 
stimulation in the heart is already excessively elevated.  Further sympathetic 
stimulation thus becomes deleterious, as the increased oxygen demand cannot be 
appropriately met by coronary blood flow.  Furthermore, prolonged β-AR stimulation 
activates multiple cellular processes involved in adverse cardiac remodeling and, 
perhaps most importantly, as an adaptive response to increased catecholamine 
levels, β-ARs desensitize naturally through receptor down-regulation and decreased 
downstream signaling.  Therefore, in an environment where β-ARs are already 
resistant to activation, β-AR agonist treatment is maladaptive [25].            
 
These new discoveries provided the intellectual basis for β-AR blockade therapy in the 
early 1960s.  In 1962, together with JS Stephenson, Sir James Black introduced a non-
selective β-blocker, pronethalol, which showed strong antiarrhythmic effects in 
guinea pigs and dogs [26].  Similar effects were seen in the clinic, and from then the 
field grew as more β-blockers were developed with more selectivity, and less toxicity.  
 
Though originally considered counterintuitive, today the administration of β-blockers 
for treating heart failure is almost taken for granted.  Now often prescribed with 
angiotensin-converting enzyme (ACE) inhibitors, which decrease vasoconstriction 
[27], β-blockers work to effectively decrease the workload placed on the heart. 
However, the cellular and molecular mechanisms governing these improvements in 
cardiac function are still being elucidated.  Mechanistic studies are further 
confounded by the fact that some of the later generations of β-blockers show only 
weak blockade and can have off-target effects, such as vasodilation, but still reach 
salutary endpoints.  Future studies will need to focus on identifying other aspects of 
the β-AR cascade for potential therapeutic intervention, and on characterizing the 
etiology and pathogenesis of the various cardiomyopathies leading to heart failure to 
develop disease-appropriate therapies.   
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Figure	4:	Schematic	showing	the	key	players	in	the	ECC	and	β-adrenergic	signaling	pathways.		Action	
potentials	activate	LTCC	allowing	Ca2+	to	enter	the	cell.		This	binds	and	activates	RyR2	allowing	for	Ca
2+	
to	leave	the	SR	and	enter	the	cytosol.		The	cytosolic	Ca2+	activates	the	myofilament	via	binding	to	TnI,	
causing	contraction.		The	β-adrenergic	signaling	can	further	enhance	contraction	via	cAMP-mediated	
PKA	 signaling,	 which	 is	 able	 to	 modulate	 various	 aspects	 of	 the	 ECC	 mechanism	 to	 increase	
contractility.		Image	adapted	from	[25].	 	  
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The Pathological Heart 
 
 											
3 The Pathological Heart 
 
Given the delicate complexity of the circulatory system, it is no surprise that there 
exists a large array of potential confounders.  Cardiovascular disease, or “heart 
disease”, is an umbrella term describing the wide range of conditions that can 
deleteriously affect cardiac function.  Diseases under this umbrella include, but are 
not limited to: 
 
• Congenital  heart defects (birth defects), which restrict blood flow to, 
from, and within the heart 
• Acquired heart defects, such as stenosis of heart valves, arteries, or veins 
• Blood vessel diseases, such as coronary artery disease (CAD) or stroke, 
which can limit the amount of oxygen reaching the heart muscle itself 
• (Si lent) Cardiac ischemia, which is a form of CAD producing few 
symptoms but resulting from insufficient oxygen delivery to the heart  
• Myocardial  infarction (heart attack), which occurs when part of the heart 
muscle is damaged due to lack of nutrients or oxygen, usually due to advanced 
CAD 
• Heart rhythm dysfunction, such as ventricular arrhythmias, which disrupt 
the heart’s electrical signaling 
• Angina, which is transient discomfort from limited oxygen and nutrient 
delivery to the heart 
• Heart infections, such as myo- and endocarditis, which occurs when 
bacteria, fungi, or other pathogens infect the endocardium  
• Cardiomyopathy, which is a family of heart diseases affecting cardiac cells 
themselves, often with genetic etiology 
3 
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• Hypertensive heart disease, which includes heart diseases stemming 
from high blood pressure  
• Heart fai lure, which can occur as a result of diabetes, lung disease, or any of 
the aforementioned cardiac conditions, and is defined as the inability of the 
heart to pump enough blood to meet the body’s needs    
 
This investigation is primarily focused on the pathogenesis and pathophysiology of 
cardiomyopathy and heart failure, so in this chapter I will provide a brief description 
of the pathogenesis of systolic and diastolic heart failure, with specific focus on the 
contributions from dilated cardiomyopathy. 
 
3.1 Heart Failure 
 
The heart muscle can fail because it is too weak to carry out normal functions or 
because it is too stiff to act as an efficient pump.  It is important to note that heart 
failure is not simply one disease, but a chronic and progressive condition that can 
arise from a number of structural and functional cardiac disorders, from diabetes, 
or from lung diseases such as emphysema. When heart failure syndrome presents 
with an EF less than 40 percent, the dysfunction is most often referred to as “systolic 
heart failure” because the ventricles are unable to perform an effective systole.  
Conversely, “diastolic heart failure” occurs with preserved EF, but overly stiff 
ventricular walls result in inefficient diastolic filling.  In this case, while the heart 
muscle maintains the strength to pump the blood to the body, there is simply not 
enough blood collected in the left ventricle at the end of diastole. 
 
The primary symptoms of heart failure include peripheral fluid retention, fatigue, and 
dyspnea (labored breathing).  The retention of excess fluid increases pressures in the 
heart, lungs, and the rest of the body, which is called “congestion”.  Congestive heart 
failure on the left side of the heart can lead to shortness of breath after modest 
activity or even at rest.  On the right side of the heart the elevated venous pressures 
can lead to the peripheral edema and abdominal swelling [28].                   
3.1.1 Systolic Heart Failure 
 
Systolic heart failure is the most common type of heart failure in patients younger 
than 65 years.  The most common causes of systolic heart failure are cardiomyopathy 
and coronary artery disease, the latter often resulting in myocardial infarction.  
Systolic heart failure is also often associated with enlargement of the heart, likely due 
to hypertrophic or dilated cardiomyopathies. 
 
The decreased EF related to systolic heart failure can lead to decreased blood flow 
during periods of increased physical activity, causing fatigue and exhaustion.  In 
advanced cases, cardiac output can even be lower than normal at rest.  If the 
reduction in cardiac output is life threatening it is called cardiogenic shock [28].    
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3.1.2 Diastolic Heart Failure 	
While heart failure is most commonly associated with systolic dysfunction, as many as 
30-40% of heart failure patients have normal or only slightly reduced EF [29].  In these 
cases diastolic dysfunction is implicated as the major contributor.  If the left ventricle 
is stiff, it relaxes too slowly in early diastole and offers greater resistance to filling.  
This stiffness is often caused by the presence of fibrotic tissue, which can arise from 
cardiac injury or as a result of adverse ventricular remodeling. The increased 
resistance thus increases diastolic pressures and results in significantly decreased 
cardiac output.  As in systolic heart failure, the low cardiac output is manifest as 
fatigue and shortness of breath.  However, unlike in systolic heart failure, the 
increased end diastolic pressure is transmitted backwards to the pulmonary venous 
system, resulting in dyspnea.  This is particularly evident in times of physical exertion. 
 
The diagnosis of diastolic heart failure depends on the simultaneous satisfaction of 
three conditions: (1) presence of the signs and symptoms associated with heart 
failure; (2) presence of normal or only slightly decreased EF; and (3) increased 
diastolic pressure or impaired filling [29].  Primary diastolic dysfunction is typically 
seen in patients with hypertension, restrictive, or hypertrophic cardiomyopathy and 
has a disproportionately high prevalence in the elderly.  
 
3.2 Cardiomyopathy 	
As opposed to other heart diseases, which primarily affect cardiac oxygen and 
nutrient consumption via blood flow, cardiomyopathies form a family of heart 
diseases affecting the heart muscle itself.  The cardiomyopathy family can be 
further subdivided into hypertrophic cardiomyopathy (HCM), restrictive 
cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy (ARVC), left 
ventricular non-compaction cardiomyopathy (LVNC), and dilated cardiomyopathy 
(DCM).  Though most of these diseases have genetic origins, the discovery of 
various acquired cardiomyopathies, as well as overlapping symptoms, often 
complicate diagnosis.  Interested readers are directed to the Cardiomyopathy 
Compendium recently published in Circulation Research for a more in-depth 
review of each cardiomyopathy [30].  As the current investigation is primarily 
focused on dilated cardiomyopathy, here I will present a brief overview of its 
known genetic determinants and mechanisms, estimations of its prevalence, and 
common treatments.            
3.2.1 Dilated Cardiomyopathy 	
DCM is characterized, generally, by left ventricular enlargement concomitant with 
systolic dysfunction (Figure	5).  This manifests clinically as (1) FS < 25% or EF < 45%, 
and (2) as an LVEDD > 117% [31].  Confusion often arises when diagnosing DCM due 
to the fact that its most common cause is in fact ischemic injury.  However, because 
DCM is a condition with multiple etiologies, it must be subdivided further into 
ischemic and non-ischemic forms.  Approximately 50% of all DCM cases are ischemic 
in origin, but after identifying left ventricular dilatation and systolic dysfunction, an 
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etiological assessment must be performed.  If no cause other than genetic can be 
identified, a clinical diagnosis of ‘idiopathic’ DCM (iDCM) is assigned.  These are the 
cases that comprise the “non-ischemic DCM” category.  The prevalence of DCM is 
estimated to be between 1:400 and 1:250 individuals in the United states [31], but 
without a formal, population-based epidemiological study, this estimate cannot be 
confirmed. 
 
Oftentimes the genetic variations leading to DCM are found to be heritable, and are 
grouped accordingly as familial DCM.  It is estimated that between 20-35% of 
identified DCM cases are familial, but the classification of familial DCM is assigned 
according only to phenotype and pedigree assessments, not molecular genetic data.  
Familial DCM can therefore be easily misdiagnosed or missed completely due to 
incomplete family history or simple professional oversight.  
 
While it may still be difficult to assess the true prevalence of 
DCM, a multitude of causal genes have been reported from 
the identified cases to date [32].  Mutations in more than 30 
causal genes have been identified and, in contrast to the 
genes associated with other cardiomyopathies, have quite 
diverse ontologies.  Many are sarcomeric genes, the most 
common of which is TTN encoding the large sarcomeric 
protein titin [33], but there is also a large proportion 
encoding Z-disk proteins, ion channel proteins, proteins 
encoding the nuclear envelope, heat-shock chaperones, and 
mitochondrial proteins. The majority of DCM-associated 
mutations are rare, or even unique to a family. The 30+ 
causal genes that have been discovered to date are 
estimated only to account for approximately 40% of the 
genetic cause of DCM [31].   
 
As with most cardiomyopathies, the current treatments for 
DCM patients are primarily focused on symptom 
management.  DCM treatment is focused on arrhythmia 
surveillance and treatment, managing LV dimension and 
function, and dealing with any apparent congestive 
symptoms [34].  Today, symptomatic DCM with HF and 
depressed EF is treated with ACE or angiotensin receptor 
inhibitors, along with β-blockers, aldosterone antagonists, 
and in some cases, general vasodilators.  These medications 
exploit the various cellular mechanisms described above to 
reduce blood pressure and decrease the overall workload 
placed on the heart.  Arrhythmogenic DCM patients are 
treated according to the standard guidelines for sudden 
cardiac death management and implantable cardioverter 
defibrillator implantation.  Those patients presenting with a 
disease-causing genotype but no evidence of pathology are 
simply monitored yearly and sometimes advised against 
Figure	5:	(A)	Normal	vs.	(B)	DCM	heart.	
Image	adapted	from	[3].			
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strenuous physical activity.  Perhaps a better understanding of the molecular genetics 
of these disease-causing genes would help physicians to reach a consensus on the 
proper medical management of this last group, but it is clear that uncovering the 
other genetic mutations leading to DCM will broaden our understanding of its 
pathophysiology, help increase the efficacy of diagnosis, and of course aid in the 
development of much more effective and comprehensive therapies.  
3.2.2 Cellular and Molecular Basis of Cardiomyopathy 
 
Despite the many different classifications of cardiomyopathy, there is a marked 
overlap in associated symptoms, emphasizing the relatively limited range of cellular 
responses within the cardiomyocyte.  With the exception of DCM, the changes in 
cellular morphology, gene expression patterns, and metabolism associated with 
cardiomyopathies are initially compensatory, but prove insufficient or even 
maladaptive in the long term.  In DCM patients, the dilated phenotype 
decompensates rapidly after the appearance of symptoms, with no observable 
compensatory mechanism [35]. 
	
Figure	 6:	 Molecular	 schematic	 of	 a	 cardiac	 sarcomere	 and	 associated	 transmembrane	 and	 ECM	
proteins.	 (A)	 Overview	 image	 of	 primary	 sarcomere	 components.	 (B)	 Detailed	 representation	 of	
functional	 players	 in	mechanotransduction,	 calcium	 sensing,	 and	 contraction.	 Image	 adapted	 from	
[35].			
In an attempt to relieve the mechanical strain placed on the heart, ventricular 
cardiomyocytes enlarge resulting in cardiac hypertrophy.  This response is considered 
to be initially compensatory as it normalizes ventricular wall stress and increases the 
heart’s contractile capacity.  Cardiac hypertrophy is due to the addition of sarcomeres 
either in series (eccentric) or in parallel (concentric) within the cardiomyocytes 
themselves, thus increasing cardiomyocyte length or width, respectively [36].  
Concentric hypertrophy increases force generation in stressed cells, but also causes 
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misalignment of the cardiomyocytes, which can negatively affect contractility [37].  
Furthermore, persistent hypertrophy of either type correlates with HF onset.  Further 
addition of sarcomeres after the initial compensatory period results in increased 
cardiomyocyte length/width ratios, which actually reduces force generation.  
Additionally, eccentric hypertrophy is associated with ventricular dilation in DCM and 
HF, and demonstrates limited compensatory function [38]. 
 
On the genetic level, cardiomyopathy results in the induction of a gene program 
typically associated with embryogenesis.  The expression of natriuretic factors – atrial 
natriuretic factor (ANF) in the atria, and brain natriuretic peptide (BNP) in the 
ventricles – induce diuresis and vasodilation to reduce blood pressure in response to 
increased wall stress.  The expression of these genes appears to be a cardioprotective 
mechanism, and there is evidence to suggest an anti-hypertrophic effect [39, 40].  
Increased expression of the β-MHC isoform also occurs with pathology.  The 
expression of the two myosin heavy chain isoforms, α- and β-MHC, occur in such 
exceptionally regulated ratios that an increase in β-MHC with concomitant decrease 
in α-MHC is a sensitive marker for early cardiomyopathy.  This response may also be 
initially adaptive, as β-MHC demonstrates improved ATP usage due to lower ATPase 
activity.  However, myofilaments with high β-MHC levels are also slower to contract, 
which may contribute to overall dysfunction [41-43].   
    
Fibrosis is a well-known hallmark of cardiomyopathy, and fibrotic tissue is composed 
primarily of collagens type I and III.  Fibrosis occurs in the early stages of 
cardiomyopathy but increases with disease progression.  Eventually the fibrotic tissue 
disrupts ECC interactions between the cardiomyocytes and causes increased 
myocardial stiffness resulting in decreased contractility.  The collagen is typically 
produced by activated resident fibroblasts, but there is also evidence supporting 
collagen production by stressed cardiomyocytes [44].  
 
The increased demand for ATP during pathology progression results in decreased 
availability of energy-rich resources, such as phosphocreatine.  In the initial stages of 
cardiomyopathy, the heart’s metabolism adapts to utilize more free fatty acids, which 
is slightly less efficient.  In DCM and end-stage HF, energy substrate utilization shifts 
from fatty acid utilization to the even less efficient glucose metabolism.  This shift is 
thought to occur as a consequence of increased cardiac growth with insufficient 
angiogenesis, thus decreasing the oxygen available for efficient oxidative metabolism 
[45].  This quasi-hypoxic state causes the expression of genes facilitating anaerobic 
glucose metabolism [46, 47].  
 
These cellular responses are primarily mediated by ECM-sarcomere connections 
(Figure	 6), and aim to maintain contractile force and steer metabolism towards 
efficient substrate utilization.  These responses are achieved through various signaling 
pathways including, mechanotransduction signaling [48], Akt and PI3K signaling [49], 
G-protein signaling [35], Ca2+ regulation and calcineurin signaling [50], and even 
apoptotic signaling pathways [51, 52].  As with their physiological sequelae, the 
activation of these pathways is initially cardioprotective, but chronic activation is 
often associated with decompensation and heart failure.    
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Modeling Cardiomyopathy 
and Heart Failure 
 
 								
4 Modeling Cardiomyopathy and Heart Failure  	
In order to better understand the mechanisms governing the onset of 
cardiomyopathy and heart failure, researchers have developed numerous tools to 
model various cardiac pathologies.  In general terms, a biological disease model can 
be defined as an animal or cell population that displays all or some of the pathological 
processes that are observed in the actual animal or human disease.  These model 
systems help us to simplify complex biological processes, to glean valuable 
information regarding the development of the disease, and to test potential 
treatment approaches. 
 
The complexity of the cardiovascular system in particular requires models that are 
exceptionally precise and robust.  Furthermore, as most models have clinical 
translation as the ultimate endpoint, it is especially important for heart disease 
models to be physiologically relevant. Cardiovascular disease paradigms have been 
developed in small mammals such as the rat, rabbit, and cat; in large mammals such 
as the non-human primate, dog, sheep, and pig; and even in non-mammalian 
vertebrates such as newts and zebrafish.  However, due to its high genetic similarity 
to the human, its short gestation period, and the relative ease of genetic 
manipulation, the common house mouse, mus musculus, has become the organism 
of choice for modeling cardiovascular disease in vivo.  In vitro studies have made large 
use of isolated neonatal rat ventricular cardiomyocytes (NRVMs), though isolated 
adult mouse ventricular cardiomyocytes (AMVMs) also offer unique benefits.   
 
In this chapter I will introduce cell-based cardiac disease models as well as the most 
commonly used whole animal-based cardiac injury model systems.  I will provide an 
overview of the currently accepted techniques for neonatal and adult cardiomyocyte 
isolation, culture, and functional characterization, and provide an introduction to 
mouse transgenesis.              
 
4 
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4.1 In vitro Models of Cardiac Disease  
 
The versatility, cost-effectiveness, and convenience of cell-based disease models has 
made in vitro modeling attractive in the field of cardiovascular research. The large 
amount of material obtained from a single preparation of cells allows for more 
biologically comparable experiments and even provides the potential for high-
throughput drug screening for the eventual discovery of novel therapeutics.  
Additionally, cell-based modeling also affords the unique opportunity to investigate 
cell-autonomous responses to cardiac insult and injury such as hypertrophy or cell 
cycle activation.  Preparations of heart cells have been reported for numerous 
species, with the neonatal rat and the adult mouse being the two most common 
sources for cardiomyocytes [53].   
 
4.1.1 Neonatal Rat Ventricular Cardiomyocyte Isolation, Culture and 
Functional Characterization 	
Like the mouse, the rat shares a high level of genetic and genomic similarity to the 
human, making it a suitable model system for translational experimentation.  
However, its advantages over the mouse for in vitro cardiac research stem primarily 
from technical and economic considerations.  In the case of neonatal cardiomyocytes, 
mice and rats exhibit similar cytoskeletal structures, metabolic properties, and protein 
signaling, making them relatively equal models systems [53].  However, hearts from 
newborn rats are larger in size, enabling a much larger yield of cardiomyocytes from a 
single preparation.  
 
The relative ease of isolation, culture, and genetic manipulation also makes NRVMs an 
attractive model system.  Because rat pups are larger than mouse pups, the actual 
dissection of the heart from the neonatal rat is much easier and, in comparison to 
adult cardiomyocytes (from either rats or mice), the cardiomyocyte isolation 
procedure is markedly less complex.  After removal of the hearts from the rat pups, 
they are minced and subject to a series of enzymatic digestions.  Two to three rounds 
of digestion are typically carried out using an enzyme buffer containing common salts, 
glucose, and a mixture of pancreatin and Collagenase Type II (Collagenase B) [54]. The 
result of the digestion step is a single-cell suspension of cardiomyocytes that are then 
plated in a mammalian cell culture media. Once plated, the cells can be cultured for 
weeks and used for subsequent experimentation.  
 
Isolated NRVMs have been used extensively to model various disease paradigms via 
genetic manipulation.  NRVMs lend themselves to genetic manipulation due to the 
relative ease and efficiency of nucleic acid delivery.  Numerous studies have reported 
very efficient gene knockdown with siRNAs [55-57], effective overexpression has been 
achieved using adenoviral DNA delivery [58-60], and miRNAs have recently proven to 
be influential regulators of cardiac development and regeneration [61-65].  Unlike 
with in vivo experimentation, this scale allows investigators to study the effects of a 
single gene on any aspect of the cellular machinery – from the level of protein-DNA 
interactions to changes in overall cellular morphology – with little to no background 
from other cell types.  Additionally, this format lends itself well to high-throughput 
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screening platforms [66], the likes of which have been used to discover novel small-
molecule inhibitors of cardiac hypertrophy [67] and potential miRNA drivers of 
cardiomyocyte proliferation [68].        
 
However, while many of the signaling pathways and protein expression patterns in 
NRVMs are similar to adult cardiomyocytes, this model system has garnered 
significant critique due to its structural disparities.  The lack of clearly defined 
sarcomeres in neonatal cardiomyocytes weakens studies of cardiomyocyte structural 
and contractile changes, and the lack of t-tubules complicates ECC investigations 
(Figure	7A).  It is for this reason that many researchers have turned to isolated adult 
cardiomyocytes for their in vitro studies.  Though they are much more difficult to 
isolate and culture, these cells have clearly defined cytoskeletal structures that more 
directly mimic human cardiomyocyte morphology (Figure	7B).     
	
Figure	 7:	 (A)	 Isolated	 neonatal	 rat	 ventricular	 cardiomyocytes	 in	 culture.	 	 The	 cytoskeletal	 protein	
alpha-actinin	 is	 stained	 in	 red.	 	Nuclei	are	 stained	blue	with	DAPI.	 	 (B)	Brightfield	 image	of	 isolated	
adult	mouse	ventricular	cardiomyocytes	in	culture	showing	clear	rod-shaped	morphology	as	opposed	
to	 the	 less-uniform,	 immature	 morphology	 of	 the	 neonatal	 cardiomyocytes.	 	 Image	 of	 AMVMs	
adapted	from	[69].						
4.1.2 Adult Mouse Ventricular Cardiomyocyte Isolation, Culture, and 
Functional Characterization 	
The early studies using adult ventricular myocytes saw them isolated from relatively 
large animals, such as cats, dogs, and rabbits, thus yielding large amounts of cells per 
isolation [70-72].  Cardiomyocytes have also been successfully isolated from guinea 
pigs [73], but because of the relative ease and cost-effectiveness of isolation, the 
adult rat has become the most commonly used animal model to date.  Though the 
adult rat ventricular cardiomyocytes (ARVMs) have been used as an in vitro model for 
over 40 years [74], no clear universal isolation protocol has been established.  
Researchers typically follow protocols that maintain the same basic principle of 
retrograde perfusion of the heart with an enzyme solution, but vary significantly in 
key details such as enzyme concentration, perfusion rate, apparatus, and dissociation 
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methods.  These disparities, while seemingly minor, can affect the reproducibility of 
results obtained from ARVM experiments. 
 
The isolation procedure of adult mouse ventricular cardiomyocytes (AMVMs) is much 
the same as that for rats [75], with the added complications that mouse hearts are 
smaller, more difficult to manipulate, and yield less cells.  However, for many 
researchers, the opportunity to study the effects of transgenic manipulation in adult 
mice on the cellular level offsets the decreased isolation efficiency.  Using this system, 
researchers are able to study the cellular effects of long-term cardiac challenges such 
as altered gene expression, fibrosis, or tissue remodeling.  In some cases, for studying 
acute effects, it is more advantageous to treat WT adult cardiomyocytes with 
hypertrophic agonists [76], but many sound conclusions regarding altered cardiac 
function in disease have been drawn from studies using isolated AMVMs from 
transgenic animals [76-78].  Furthermore, as AMVMs have become more popular as a 
model system, isolation and culture procedures have become more widespread and 
standardized [79, 80].  However, because certain physiological characteristics of 
isolated adult ventricular cardiomyocytes can change over time in culture, most 
experiments with these cells must be performed within 24 – 48 hours to maintain the 
morphological and behavioral similarities to cells in intact tissue.  
 
Indeed, the greatest advantage of using adult ventricular cardiomyocytes as a model 
system for cardiac disease is their similarity to cells in intact tissue.  Cardiomyocytes 
isolated from adult mammals are rod-shaped, are often binucleated, have a well-
organized sarcomeric structure, and exhibit contractile function when paced with an 
electrical stimulus.  The ability to control the pacing frequency permits another level 
of experimental control and has been suggested to create a more physiological 
environment for the cells [81].  This unique characteristic of isolated adult 
cardiomyocytes also presents the possibility to employ cell-based electrophysiological 
methods, such as a patch clamp and calcium transient analysis, in a much more 
physiologically relevant setting.   
 
4.1.2.1 Measuring	Ion	Channel	Dynamics	Using	Patch	Clamp	
The patch clamp technique is an innovation of the traditional voltage-clamp recording 
techniques pioneered by Kenneth Cole, Alan Hodgkin, and Andrew Huxley.  The aim 
of this technique is to measure and characterize the currents through the ion 
channels of excitable (and non-excitable) cells.   
 
The first step of all patch-clamp recordings is to establish the high-resistance (≥1-10 
GΩ) seal between the patch pipette and the cell membrane.  When the patch pipette 
is close to the cell membrane, the application of suction will create a tight seal 
allowing for direct current measurement.  If the suction is not too great as to break 
the cell membrane, the result is a “cell-attached” configuration, allowing the most 
physiological readings, as the contents of the cytosol remain undisturbed.  However, 
the membrane potential of the membrane cannot be quantified using this 
configuration.  By applying a stronger negative suction or a high-frequency voltage 
pulse across the membrane, a rupture can be formed creating a low-resistance 
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pathway between the cell’s cytoplasm and the ionic solution inside the pipette.  This 
“whole-cell” configuration allows for control of the composition of both the 
intracellular and extracellular compartments, permitting the measurement of voltage 
potential changes as well as macroscopic current changes across the entire cell 
membrane.  The whole-cell patch clamp technique is routinely used for investigating 
gross changes in cardiomyocyte electrophysiology due to disease or injury, but 
studies focused on small molecule validation would most likely use the “inside-out” 
configuration.  This is achieved by pulling back the patch pipette after a gigaseal has 
been created in the cell-attached configuration.  This allows researchers to test the 
effects of small molecules or proteins on specific ion channels, by adding them 
directly to the pipette solution.  The final common configuration is the “outside-out” 
configuration, which is obtained from the whole-cell configuration by pulling back the 
patch pipette.  If the gigaseal is stable enough, the two parts of the membrane will 
anneal allowing for voltage and current measurements.  This configuration allows for 
the investigation of the effects of extracellular proteins on ion channel function, with 
single-channel resolution [82].  
       
	
	
	
	
Figure	 8:	 Representative	
contributions	 of	 common	 ion	
channel	currents	 in	 (A)	human	
and	 (B)	 mouse	 ventricular	
cardiomyocyte	action	potential	
generation.	 	 In	 both	 cases	 the	
depolarization	 due	 to	 the	
cardiac	sodium	current	is	a	key	
action	 potential	 initiator.	
Image	adapted	from	[83].	
The whole-cell patch technique has been very successful in describing the properties 
of membrane currents in cardiomyocytes.  Most approaches make use of 
pharmacological inhibitors, often included in the patch pipette solution, to isolate 
particular currents of interest for analysis.  Currents are sometimes measured before 
and after blockage and subtracted to yield the “blocker-sensitive” currents. 
Tetrodotoxin (TTX) and Cd2+ (CdCl2) are commonly used for blocking inward Na
+ and 
Ca2+ currents, respectively.  Addition of Cs+ and tetrathylammonium (TEA) to the 
pipette solution is often used to block outward K+ currents.  Additionally, some more 
specific voltage-clamp protocols use step depolarizations or hyperpolarizations of 
fixed duration (sometimes also in combination with blockers) to target specific 
current components [82] (Figure	8). 
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4.1.2.2 Quantifying	Calcium	Dynamics	and	Contractility	Using	IonOptix																	
Because of the large role that calcium plays in the molecular function of the heart, 
understanding Ca2+ dynamics is of upmost importance when investigating cardiac 
dysfunction.  The well-defined sarcomeric structures of isolated adult cardiomyocytes 
allow for direct contractility measurements using light-phase microscopy upon 
electrical field stimulation, and numerous calcium-activated fluorescent dyes have 
been developed to quantify the resultant localized changes in [Ca2+]i, often referred 
to as calcium “sparks”.  The summation of these calcium sparks over the entire cell 
represents the transient increase in [Ca2+]i during each contraction, and is thus 
termed the calcium transient.   
 
The first reports of measurable calcium transients during cardiac EC coupling were 
made in 1978 by David G. Allen who quantified aequorin luminescence in frog cardiac 
muscle [84], and by Gil Wier in 1980 who injected photoproteins into canine Purkinje 
fibers [85].  Since then, innovations of calcium-activated fluorescent dyes have 
improved their sensitivity and precision through the addition of an acetoxymethyl 
(AM) ester group, enabling cell permeability, and by engineering a shift in the 
maximum excitation wavelength upon Ca2+ binding, allowing for ratiometric 
quantification of [Ca2+]i.  Today, advanced digital imaging techniques, such as laser 
scanning confocal microscopy, have allowed researchers to visualize contraction 
events and trace calcium transients in isolated adult cardiomyocytes in real time.  
Various companies, such as IonOptix, have also now developed commercial hardware 
to record these data as well as multivariate analysis software for subsequent data 
analysis.   
 
The IonOptix system is able to combine brightfield imaging with sarcomere and cell-
length detection algorithms to translate image data from recordings of single cells to 
quantifiable displacement transients describing contractility in real time.  Monotonic 
transient analysis is then often used to report various parameters describing the 
characteristics of the transient, which can be used as markers of physiological 
function.  Peak contractile shortening/re-lengthening velocities and percent 
sarcomere/whole cell shortening are often reported for contractile studies; the latter 
often being considered analogous to fractional shorting in whole heart studies. In the 
case of calcium transients, the IonOptix system records the fluorescence of 
intracellular Ca2+ indicators in real-time to create plots depicting the change in [Ca2+]i 
with time.  The same monotonic transient analysis methods can be applied to these 
transients to quantify rates of calcium release and reuptake, peak [Ca2+]i, and time to 
recovery of baseline Ca2+ levels.                    
 
The unidirectional flow setup of the IonOptix system also lends itself well to testing 
the effect of proteins or pharmaceuticals on cardiomyocyte contractility and calcium 
handling.  Because of the in-line profusion system, the drug of interest can simply be 
added to the perfusion buffer for a given time, and the effect can be recorded. This 
technique has been used extensively to investigate various pharmaceutical 
modulators of contractile function and calcium handling [86-88].    		
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4.2 In vivo Models of Cardiac Disease 	
While much can be gained from in vitro cardiovascular studies, because a single cell 
cannot accurately represent the functionality of an entire tissue or organ system, cell-
based experimentation also has many disadvantages.  In vitro studies are well suited 
for investigating the cell-autonomous consequences of genetic manipulations or 
pharmaceutical treatments, but it is often very difficult to fully recapitulate the effects 
of gross cardiovascular injury, such as myocardial infarction or cardiac ischemia.  In 
vivo studies however offer researchers the opportunity to investigate the effects of 
injury or genetic manipulation at the whole-organ and whole-organism level.  This is 
especially important for regenerative studies, as multiple cell types and organ systems 
are involved in the regenerative response, as well as for preclinical testing, in which 
off-target effects can prove dire.  Furthermore, as most in vitro studies are conducted 
using homogenous cell populations, the effects of intercellular signaling cannot be 
examined.  By studying the entire organism, researchers are also able to uncover 
endocrine and paracrine signaling pathways, the drivers of which could form the basis 
for novel therapeutics.  
4.2.1 Commonly Used Disease Paradigms for Cardiac Injury 	
The need for animal-based models of cardiovascular disease stems primarily from the 
need for a suitable system for preclinical testing of potential pharmaceuticals or 
treatment strategies.  The ideal model system for such studies would be donated 
human hearts themselves, but the paucity of material, the inherent variability of 
human samples, as well as the priority given to transplant patients makes this avenue 
impractical. Both large- and small-animal models of cardiac injury have been 
developed to this end [89, 90], but for the purposes of this report, only mouse models 
of cardiovascular disease will be discussed.     
4.2.1.1 Ligation-induced	Models	of	Myocardial	Infarction	(MI)	and	Ischemia	
Reperfusion	(IR)	
The adult mouse model of MI is one of the most commonly used models of 
cardiovascular disease, as it has been shown to recapitulate the human response to 
ischemic injury accurately enough to yield physiologically relevant results [91, 92].  To 
achieve the infarction, the mice are first anesthetized and intubated for ventilation, 
then subject to a left-sided thoracotomy to expose the left anterior descending (LAD) 
coronary artery for permanent ligation.  The ligation of the LAD blocks the flow of 
blood to the heart, resulting in an ischemia-induced MI.  The chest and skin are then 
closed, and the mice are allowed to recover.  Upon injury, inflammatory cells and 
fibroblasts infiltrate the infarct area, scar tissue replaces the necrotic myocardium 
and, as in humans, the inflexible scar tissue persists and results in markedly decreased 
cardiac functionality [93].  If MI is not the desired experimental endpoint, the ligation 
can be removed allowing for reperfusion of the myocardium [94].  In this way, a 
defined period of ischemia can be achieved, and the tissue damage associated with 
the reperfusion of ischemic myocardium can also be studied.  
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4.2.1.2 Pressure	Overload	Model	of	Heart	Failure	Using	Transverse	Aortic	
Constriction	(TAC)		
Pressure overload of the cardiac system leads to pathological hypertrophy, as the 
heart struggles to adapt to the increased mechanical load, and ultimately results in 
congestive heart failure.  In humans, this is typically caused by stenosis or blockage of 
the great vessels, disallowing adequate outflow from the heart chambers and causing 
the internal chamber pressure to rise. To model this in mice, a suture is placed 
around the aorta distal to the brachiocephalic artery.  The suture can be tightened 
around a blunt needle, with the gauge of the needle determining the severity of the 
constriction.  A 27-gauge needle is commonly used.  The needle is then removed and 
the chest and overlaying skin are closed.  The TAC procedure results in a significantly 
increased heart-weight-to-body-weight ratio, indicative of cardiac hypertrophy, and 
significantly decreased cardiac functionality [95].  
 
One major drawback of these types of in vivo injury models is the non-standardized 
experimental procedures.  Because the surgeries can be technically challenging, it is 
also difficult to ensure comparable levels of injury severity, making the translation of 
results between investigations difficult. Furthermore, as rodents and humans are 
phylogenetically distant, some of the pathophysiological features of disease may not 
be reliable predictors of human physiology.  However, both the LAD ligation and TAC 
techniques have given researchers a much broader understanding of the 
pathogenesis of MI and HF, and employing these techniques in transgenic 
backgrounds has provided invaluable insights into the effects of specific genes on 
disease progression. 
4.2.2 Transgenic Mouse Models of Cardiomyopathy  
 
Perhaps the foremost advantage of using the house mouse, mus musculus, for 
biological experimentation is the relative ease of genetic manipulation. Most 
transgenic mouse models of CVD are focused on modeling cardiomyopathies through 
gene knockout, overexpression, or mutation.   
 
The primary goal of gene knockout or mutation is to isolate the effects of the target 
gene by ablating its expression or modifying its activity, and assessing the 
morphological and/or functional consequences.  This is typically accomplished by 
replacing the endogenous gene with in an engineered sequence encoding an 
inoperable gene product.  The construct containing the mutated gene is usually 
introduced into cultured mouse embryonic stem cells via electroporation, where it 
will be naturally integrated into the genome of some of the cells.  The cells containing 
the gene are isolated and inserted into the blastocyst of another mouse.  The 
blastocyst is allowed to develop in the uterus of a female mouse.  The resulting 
chimera is mated with a wild-type mouse, and after two generations, a mouse 
homozygous for the gene knockout can be obtained.  However, loss of genes that are 
critical for development can lead to embryonic lethality.  As mice containing 
embryonic lethal constructs do not come to term, the use of these model systems is 
limited to studies of the embryonic fibroblasts [96, 97].     
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The technique for gene overexpression is somewhat less complex.  In this case, the 
construct containing the gene or mutation to be overexpressed can be injected into a 
singe cell of the mouse embryo.  The construct is then randomly incorporated into 
the genome, and mice expressing the construct will begin to express the protein at 
higher levels depending on the integration locus and the number of copies integrated.  
One particular drawback of these types of overexpression systems is the propensity 
for artificially high protein overexpression [98].  In these cases, the high 
overexpression can lead to non-physiological responses that do not recapitulate 
human disease and therefore cannot provide translatable results. 
 
To circumvent some of these difficulties, scientists have made use of tissue-specific 
and inducible gene expression systems.  By expressing the gene of interest under the 
control of a tissue-specific promoter, researchers can restrict the expression of their 
target gene to a single tissue or cell type.  In cardiac research, the α-myosin heavy 
chain (αMHC) promoter has been used extensively to restrict gene expression to 
cardiomyocytes [43].  In so doing, genes that may have been embryonic lethal when 
overexpressed or knocked out ubiquitously can be assessed for potentially nonfatal, 
cardiac-specific phenotypes.   
 
Temporal regulation of gene expression can be achieved by using inducible 
constructs.  Various methods have been developed to this end, the most common of 
which are the Cre/Lox and tetracycline methods.  In the case of the Cre/Lox system, 
when mice overexpressing Cre-recombinase are mated to mice with a gene cassette 
containing the gene of interest downstream of a stop sequence flanked by two LoxP 
sites, the Cre-recombinase recognizes the LoxP sites and excises the “floxed” stop 
sequence allowing for expression of the gene of interest.  This method can also be 
used to for gene knockout by placing the LoxP sites on either end of the gene of 
interest directly [99].  If a tissue-specific promoter drives the expression of the Cre-
recombinase, the overexpression of the gene of interest will also be spatially 
regulated. 
 
However, in many cases, it is beneficial for the regulation of a certain gene to be 
reversible.  In these cases, the use of Tet-On and Tet-Off systems are highly beneficial 
[100].  The basis of tetracycline-mediated gene expression is the presence of a gene 
cassette containing an upstream tet-responsive element that regulates target gene 
expression depending on the presence or absence of a specific antibiotic, typically 
tetracycline itself or one of its derivatives (e.g. doxycycline (Dox)).  Tet-On systems 
activate gene expression in the presence of Dox, while Tet-Off systems activate gene 
expression in the absence of Dox.  Simply by removing or adding the antibiotic, it is 
possible to temporally regulate gene expression.  Furthermore, utilizing this 
technology in a tissue-specific Cre-mediated background allows researchers to 
reversibly modulate gene expression both spatially and temporally.                                                
 
In sum, the vast array of experimental techniques for studying the cardiovascular 
system that has been developed in the recent decades has afforded researchers the 
opportunity to discover many of the molecular drivers of cardiac development and to 
begin to determine the molecular drivers of pathology.  While these insights have 
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aided in the development of novel pharmaceutical therapies, complete functional 
recovery remains elusive.  Today’s therapies function to decrease the symptoms of 
cardiac dysfunction, slow disease progression, and can indeed prolong life, but they 
fail to address the problem of cardiomyocyte loss directly.  The next paradigm of 
cardiovascular medicine will undoubtedly be characterized by therapies that enhance 
cardiomyocyte proliferation and result in complete cardiac regeneration.  
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Cardiac Regeneration 
 
 											
5 Cardiac Regeneration 	
Recent advances in cardiovascular science and the development of various animal 
models of cardiac regeneration have given researchers a new insight into the natural 
biology of cardiac development.  We have uncovered an innate regenerative capacity 
of the mammalian heart and in so doing have elucidated a novel prospect for direct 
therapeutic intervention.  It is therefore essential to understand the magnitude, 
dynamics, and mechanisms governing this regenerative response, whether or not it 
can be enriched, and whether or not enrichment is clinically beneficial. 
 
In this chapter I will introduce the concept of cardiac regeneration beginning from the 
early discoveries in non-mammalian vertebrates.  I will then discuss modeling cardiac 
regeneration in neonatal mice, and conclude with a summary of the recent reports 
describing cardiac cell turnover in humans.     
 
5.1 Cardiomyocyte Renewal in Mammalian and Non-Mammalian 
Vertebrates 	
Despite the seemingly insurmountable insult to the organism arising from 
cardiomyopathy, many species have developed methods to overcome cardiovascular 
injury and completely regenerate the heart muscle.  Studies regarding the 
regenerative capacity of amphibians date back to the mid 18th century when 
Spallanzani described limb regeneration. Since then scientific curiosity surrounding 
this remarkable ability has grown significantly, and resulted in a deeper physiological, 
cellular, and molecular understanding of the regenerative process.  It is no surprise 
then that the first evidence of cardiac regeneration was observed in early amphibian 
studies.  Ventricular injury resulted in DNA synthesis concomitant with karyokinesis in 
5 
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newts, frogs, and axolotls, and cardiac regeneration after cardiac resection was 
reported for the first time in 1974 [101-103].  Most of the cardiac regeneration 
studies in amphibians showed reactivation of cardiomyocyte proliferation, but 
incomplete restoration of cardiac function.   However in 2011, a smaller injury 
performed by puncturing the heart wall with a hypodermic needle (as opposed to the 
earlier amputation studies) showed complete recovery [104]. A large-scale, 
systematic study of the effects of injury severity on regenerative capacity in 
amphibians will be necessary to discern whether or not these discrepancies in 
regenerative capacity are merely due to the degree of injury.  However, despite these 
slight regenerative limitations, it is clear that the capacity for self-renewal in 
amphibians far outreaches that of humans.  These first newt studies successfully 
illustrated the phenomenon of endogenous cardiac regeneration, and prompted 
scientists to investigate the conservation of this regenerative capacity in non-
mammalian and mammalian species alike.  Today, the use of amphibious species for 
cardiac research is often limited by the availability of genetic and molecular tools.  It is 
likely for this reason that researchers have turned to more genetically malleable 
species such as the mouse and zebrafish.   
5.1.1 Cardiac Regeneration in Zebrafish  	
The zebrafish heart is only 
comprised of one atrium and 
one ventricle making it a much 
simpler system than the 
mammalian heart.  It is 
approximately 1 mm3 and 
blood-flow is unidirectional 
(Figure	 9A).  However, its 
histological composition is 
similar to mammals, making it a 
suitable model organism for 
translational cardiac research 
(Figure	 9B).  Similar to 
amphibian species, adult 
zebrafish have a remarkable 
capacity to regenerate many 
organs through various, organ-
specific mechanisms [105].  For 
example, fin regeneration depends on the formation of a blastema at the injury site 
composed of highly proliferative, pluripotent, dedifferentiated cells, while 
telencephalon regeneration in the brain is blastema-independent and instead relies 
on the mobilization of the resident progenitor cell population via Notch signaling 
[106].  Studies in the teleost fish Danio rerio have proven that zebrafish are able to 
completely regenerate their hearts after cardiac injury [107], and recent studies have 
shown that regeneration is driven primarily by parenchymal cell dedifferentiation and 
proliferation [108, 109].  Interestingly, not all teleost species maintain this 
regenerative capacity [110], but in adult zebrafish (aged 1 to 2 years), 20% of the 
Figure	9:	
Common	cardiac	
injury	paradigms	
in	zebrafish.			
Adapted	from	
[2].	
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ventricular myocardium can be surgically removed from the heart’s apex with no 
discernable cardiac dysfunction after 60 days of recovery [107].  Today numerous 
studies have been performed in attempts to determine the molecular mechanisms 
governing the regenerative events in the zebrafish heart, and various cardiac injury 
model systems have been designed to that end. 
5.1.1.1 Apical	Resection	Model		
In 2002 Poss and Keating first illustrated the ability of the adult teleost Danio rerio to 
completely regenerate its heart by surgically removing ~20% of the heart apex and 
allowing the fish to recover naturally [107].  Profuse bleeding occurred directly upon 
resection, but was quickly quelled by the formation of a large fibrin clot after a few 
seconds (Figure	9C).  In as little as 7 days post-amputation (dpa), zebrafish behavior 
was indistinguishable from control animals.  The fibrin clot was replaced by new 
myocardium in the first weeks after amputation, and there was a significant increase 
in ventricular surface area between 0 and 30 dpa [107].  Increased BrdU 
incorporation suggests that this regenerative response is, at least in part, due to 
cardiomyocyte hyperplasia, and genetic fate-mapping [109] studies have since 
verified that the primary effectors in this recovery are the remaining cardiomyocytes 
themselves via a Gata4-dependent proliferative mechanism.  The most remarkable 
characteristic of heart regeneration in the zebrafish using this injury model is its lack 
of scar formation.  It has been suggested however that, as ventricular resection is 
based on tissue removal rather than cell death, scarring does not occur because there 
is no cell debris to be removed [2].     
5.1.1.2 Cryoablation	Model	
Poss and Keating’s ventricular resection model quickly became the gold standard for 
zebrafish cardiac regeneration studies, and is still used by many researchers today.  It 
was not until 2011 that the first alternative approach to apical resection was 
attempted to further challenge the regenerative capacity of the zebrafish heart.  
Chablais et. al. among others employed cryoinjury to study the regenerative response 
after a more severe insult to the cardiac system [111-113].  In this disease paradigm, 
a precooled metal filament is used to freeze a portion of the ventricular surface, 
resulting in necrosis of the contacted cells and subsequent apoptosis of the cells 
surrounding the necrotic area (Figure	9D).  This injury model is more reminiscent of 
human MI, and the apoptotic response affects all cell types, including the epicardium, 
endocardium, and the coronary vasculature.  
 
As opposed to the apical resection model, which shows no evidence of scar 
formation, cryoinjury results in transient scarring.  Shortly after injury, inflammatory 
cells infiltrate the necrotic area, and the presence of activated myofibroblasts 
contributes to the deposition of fibrotic tissue.  However, as opposed to the 
permanent scarring observed in mammalian cardiac injury, the fibrotic scar in the 
zebrafish is cleared within 3 to 4 months post injury [2].  The concomitant recovery of 
the epicardium and endocardium creates a suitable microenvironment for 
cardiomyocyte proliferation and vasculogenesis.  This suggests that in zebrafish, while 
some ventricular remodeling may occur, ventricular scarring is not an insurmountable 
hindrance to the restoration of cardiac functionality.   
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5.1.1.3 Genetic	Cardiomyocyte	Ablation	Model		
Recently, more non-invasive cardiac injury strategies have been devised involving 
inducible genetic systems to ablate cardiomyocytes via cardiomyocyte-specific 
expression of enzymes or cytotoxins.   One such strategy exploits the catalytic activity 
of the bacterial nitroreductase (NTR).  Curado and colleagues expressed NTR 
specifically in cardiomyoctyes by placing it downstream of the cardiomyocyte light 
chain (cmlc2) promoter [114, 115]. NTR is not toxic in itself, but it is able to catalyze 
the pro-drug metronidazole (Mtz) to a cytotoxic metabolite.  Thus, when Mtz is added 
to the system water, it is taken up by the fish and reduced to a cytotoxic agent 
specifically in the cardiomyocytes of the fish expressing NTR.  In this way, only 
cardiomyocytes are ablated while surrounding cells remain unharmed (Figure	 9E).  
Despite the insult the cardiac system, there is little evidence of scarring.  This system 
offers temporal control of cardiomyocyte ablation, as the Mtz can be added and 
removed from the water at will.  This method is especially beneficial for studies of 
cardiac regeneration during zebrafish development, as the embryonic zebrafish heart 
is considerably smaller rendering mechanical manipulations impractical.   
 
Another genetic ablation model, more targeted towards adult zebrafish, makes use of 
cardiomyocyte-specific expression of diphtheria toxin chain A (DTA) [116].  DTA 
expression results in diffuse ablation of ~60% of all cardiomyocytes.  The fish are able 
to tolerate this loss of cardiomyocytes, but they develop signs of heart failure.  
Remarkably, the injured hearts are completely regenerated after ~30 days with no 
apparent scarring.  
 
Because the genetic ablation models affect cardiomyocytes specifically, these disease 
paradigms are often considered to be more reminiscent of advanced cardiomyopathy 
than an MI.  Additionally, because the injuries are chemically based, the severity of 
the injury can be more easily titrated and the injury itself is much more reproducible 
in large animal cohorts.       
5.1.2 Cardiac Regeneration in Small Mammals 	
Both mature non-mammalian vertebrate hearts and embryonic mammalian hearts 
exhibit a two-chambered organization with single-circulation and contain small 
cardiomyocytes, which are primarily mononucleated [117]. The implications of these 
similarities were highlighted in 2008 when Cox and colleagues described the 
embryonic heart’s ability to compensate for a 50% reduction of tissue via 
hyperproliferation of healthy cardiac cells [118]. This finding not only elegantly 
illustrated the regenerative capacity of the fetal heart, but also indicated that the 
factors conducive to cardiomyocyte cell-cycle reentry may exhibit differential 
expression with age. It has been suggested that these cardiogenic factors comprise a 
fetal genetic program for cardiogenesis that can be reactivated upon cardiac injury 
[119].  
 
However, the mammalian regenerative response is not completely lost after birth. 
Neonatal mice possess a 7-day window for postnatal cardiac regeneration [120]. After 
15% resection of the left ventricular apex of 1-day-old mice, progressive regeneration 
results in restoration of the resected myocardium within 21 days, with normal 
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ejection fraction and systolic function present after 2 months [120]. However, this 
regenerative capacity is only maintained up to postnatal day 7, and survival rates are 
decreased in older mice. Ligation of the LAD [121, 122] and cryoinjury [123] in 
neonatal mice also result in myocardiogenesis, although only nontransmural 
cryoinjury results in complete myocardial repair [124].  Additionally, Senyo and 
colleagues have shown that cardiomyocyte renewal exists at a low rate even in adult 
mice.  By administering the non-toxic thymidine analog 15N-thymidine, and using 
multi-isotope imaging mass spectrometry, they show that cardiomyocytes are 
exchanged at a rate of 0.76% per year in young adult mice and at lower rates in older 
animals.  Of note, cardiomyocyte renewal was increased after MI, suggesting 
activation of regenerative pathways upon injury [125]. 
 
5.2 Cardiomyocyte Renewal in Humans 	
Cardiomyocyte renewal in humans is a more challenging phenomenon to investigate. 
Studies in animal model systems are able to use radiolabeled nucleotide analogs and 
various genetic modifications that cannot be readily adapted for human studies [126]. 
Early evidence for postnatal cardiomyocyte cycling in humans came from observed 
instances of mitotic segregation in postmortem studies of children with diphtheria in 
the 1920s and 30s [127, 128]. We now know that the mere appearance of mitotic 
events does not necessarily preclude cardiomyocyte division [129-132], but this 
finding suggested an innate cell-cycle activity that wanes, or is completely lost, later in 
life. Later studies have suggested that cardiomyocyte proliferation is the primary 
contributor to heart growth in infants and adolescents [133], and studies using the 
thymidine analog iododeoxyuridine (IdU) have suggested that this proliferative 
capacity is maintained in adulthood [134]. Thus, an understanding of the magnitude 
and mechanism of this phenomenon could help develop future therapeutics.  
 
However, as in mice, the controversy surrounding the magnitude and dynamics of 
cardiomyocyte turnover in the human heart has been entertaining the scientific 
community for over a decade [135-137]. Likely due to difficulties differentiating 
cardiomyocyte proliferation events from multinucleation or polyploidization, studies 
of cardiac cell-cycle dynamics have yielded markedly inconsistent results. To provide 
more concrete evidence supporting the existence of cardiomyocyte renewal in 
humans, researchers have exploited the presence of radioactive carbon isotopes (14C) 
in nuclear DNA. By adapting conventional radiocarbon dating techniques, 
cardiomyocyte turnover has been verified in adult humans.  This technique has also 
been used to determine the dynamics of cardiomyocyte and non-cardiomyocyte 
renewal [138]. 
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Radiocarbon Dating 	 			
	
Figure	 10:	 The	 carbon	 cycle	 depicting	 the	 contribution	 of	 14C	 from	 above	 ground	 nuclear	 bomb	
testing.		The	atmospheric	14C	is	incorporated	into	genomic	DNA	during	cell	renewal.		Image	adapted	
from	[139]			
6 Radiocarbon Dating 
 
The use of the radioactive carbon isotope 14C to determine the age of biological 
specimens is not a new concept.  Willard Libby first described the technique in the 
late 1940s as a method to determine the age of biological samples by determining the 
level of 14C radioactive decay [140].  Since then this technique has become the gold 
standard for dating ancient biological samples, and recent innovations have extended 
the use of this technique to tissue specimens and even cell populations. 
 
In this chapter I will introduce the concept of 14C dating and describe how it has been 
combined with accelerator mass spectrometry to quantify cell turnover in 
postmortem human heart tissue samples.  I will then provide a brief summary of the 
magnitude and dynamics of cardiomyocyte and non-cardiomyocyte cell turnover in 
humans.   
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6.1 The Carbon Cycle 	
The utility of radiocarbon dating stems from the incorporation of atmospheric 14C into 
the carbon cycle.  The 14C isotope is formed when cosmic rays, composed primarily of 
heavy atomic nuclei and high-energy protons, bombard the atmosphere’s diatomic 
nitrogen (14N2).  This liberates a proton and creates 
14C according the following 
(simplified) equation:  
 𝑵 + 𝒏𝟎𝟏𝟕𝟏𝟒 → 𝑪𝟔𝟏𝟒 + 𝒑𝟏𝟏  
 
Where n represents an unstable free neutron contained in the cosmic ray, and p the 
resulting proton. Although 14C is an unstable carbon isotope, it is still able to interact 
with atmospheric oxygen (O2) to form radioactive carbon dioxide (
14CO2). The 
resulting 14CO2 is incorporated into the biosphere via photosynthetic plants, and 
bioamplification of the radioactive element occurs through consumption.  The 14C an 
organism consumes reaches a steady state with the atmospheric 14C until the 
organism dies and ceases exchanging carbon with its environment. As the remaining 
14C decays the sample’s age can be determined by measuring the amount of 14C in a 
biological sample, relating it to the level of atmospheric 14C and adjusting for the 14C 
rate of decay (Figure	10).  
 
6.2 Retrospective Birth Dating Using Above-Ground Nuclear Bomb Tests 
 
The long half-life of 14C (5,740 years) typically does not allow birth dating of tissue 
samples, but the dramatic increase of atmospheric 14C levels from above-ground 
nuclear weapons testing during the 1950s and 1960s afforded researchers a new level 
of sensitivity, since a small time differential corresponded to a large change in 14C 
concentration [141, 142].  One of the first applications of the radiocarbon bomb pulse 
for medical research purposes was performed by Mok et. al. in 1986 using gallstones 
collected from human subjects [143]. In their study they were able to deduce the 
birth dates of each sample by comparing the 14C concentration of the samples to the 
14C bomb curve.  However, since this first application, both the carbon isolation and 
isotope counting techniques have improved dramatically. Decades of advances in 
DNA isolation techniques and the recent adaptation of accelerator mass spectrometry 
(AMS) technologies have decreased the required amount of starting material by 1 
million-fold, from the order of grams to the order of micrograms [144]. 
 
To understand the utility of radiocarbon dating of biological material one must be 
acquainted with the fundamentals of the carbon cycle. The exchange of carbon 
between an organism and the atmosphere extends even to the organism’s DNA and 
the atoms contained therein.  During each cell division, new carbon atoms are 
incorporated into the cell’s DNA. The 14C integrated into the genomic DNA reflects the 
level of 14C in the troposphere at the time of that cell’s formation.  Therefore, analysis 
of the 14C content in the nuclear DNA of a cell population can give a precise date for 
the genesis of that population [145-147]. Carbon exchange within the genomic DNA 
ceases when the cell stops dividing.  It is this crucial consideration that allows for 
retrospective birth dating of human cells.  When a cell ceases to divide, and no more 
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carbon exchange occurs, the 14C contained therein begins to decay and the genesis of 
that cell can be determined. 
 
6.3 Evidence for Cardiomyocyte Renewal in Humans 
 
To date, the radiocarbon dating technique has been used to determine the extent of 
postnatal DNA synthesis in numerous cell types [148, 149] including in the myocardial 
cells of the left ventricle, and specifically in cardiomyocytes [136, 138]. In heart tissue 
from subjects born up to 22 years before the onset of the nuclear bomb tests, the 
elevated “post-bomb” 14C concentrations illustrated the turnover of cardiac cells 
[136]. However, as cardiomyocytes constitute only 20% of all cells in the human 
myocardium, markers against the nuclear localized cardiac troponins (TnI, TnT) [136] 
or pericentriolar material 1 (PCM-1), a perinuclear myocyte marker [150], were used 
to specifically identify cardiomyocyte nuclei [151-154].  The study showed that the 
cardiomyocyte DNA was indeed younger than the individual.  Furthermore, since the 
proportion of multinucleated cardiomyocytes remains at a constant 25% throughout 
life [138] and the isolated diploid cardiomyocyte nucleus population was also younger 
than the individual, de novo nucleus formation was the only plausible explanation for 
the changes in 14C concentration.  
 
6.4 Dynamics of Cardiac Cell Turnover in the Healthy Human Heart 
 
The radiocarbon dating technique has also been used in conjunction with design-
based stereology and flow cytometry techniques to develop a comprehensive 
characterization of the natural history of cardiomyocyte generation and turnover 
[138]. Stereology techniques have shown that cardiomyocyte nuclear density 
decreases 15-fold shortly after birth and have corroborated the previous finding that 
the nucleation ratio does not change substantially during heart growth or aging. 
Interestingly, the final number of cardiomyocytes (3.2 ± 0.75 billion cells) is reached 
already 1 month after birth. These data are in accordance with early stereological 
studies showing no further increase in cardiomyocyte cell number after the perinatal 
period [155]. The radiocarbon data revealed that human cardiomyocytes are on 
average 7 years younger than the individual.  
 
Fitting the radiocarbon data to mathematical models describing turnover rates can be 
used to establish the dynamics of cell generation and renewal [148, 149]. The model 
giving the best fit to the cardiomyocyte data from healthy individuals allowed for 
turnover rates to change with time in an inverse linear declining manner.  The model 
predicts a renewal rate of 1% per year at age 25, which declines to < 0.5% by 70 years 
of age.  Interestingly, in adult humans, 40% of the cardiomyocytes present in the left 
ventricle have actually been generated after birth, but only 3% of these were 
generated after the age of 10. Although the birth rates of cardiomyocytes are highest 
during the perinatal period and in pediatric hearts, 14C-based turnover data support 
our stereological analysis, suggesting a constant number of cardiomyocytes from 
birth to death [138].  	  
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Present Investigation 
 
 											
7 Present Investigation 	
The primary aims of the present investigation were to develop a better understanding 
of the mechanisms governing cardiac dysfunction, specifically those pertaining to 
dilated cardiomyopathy and heart failure.  We also aimed to investigate the 
regenerative capacity of the pathological heart, in an attempt to uncover novel 
regenerative pathways.   
 
Secondary aims included optimizing cardiomyocyte isolation, culture, and functional 
characterization techniques, to be able to develop in vitro systems for hypothesis 
testing, and to determine key players in cardiac pathogenesis and the cardiac 
regenerative response.       
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7.1 PAPER I – Isolation, Culture, and Functional Characterization of Adult 
Mouse Cardiomyocytes 	
7.1.1 Introduction 
 
The lack of adequate cell lines reflecting the structure and function of adult 
cardiomyocytes has been a significant limitation in the development of in vitro 
modeling systems for cardiovascular disease.  Primary neonatal cardiomyocytes have 
been used successfully to illustrate vital signaling pathways and to test the effects of 
genetic manipulation, but their immature cytoskeletal structure and markedly 
different subcellular organization from adult cardiomyocytes renders them 
inadequate for the investigation of ECC or ion fluxes.  It is for this reason that 
researchers have turned to isolated adult cardiomyocytes, as these cells maintain the 
complex cytoskeletal structure seen in intact tissue samples and are electrically 
excitable, allowing for much more physiologically relevant studies of electrochemical 
dynamics, excitation-contraction coupling, and molecular signaling cascades.   
 
Adult rat ventricular cardiomyocytes have been used extensively to this end, but 
because of the relative ease of transgenic manipulation, the adult mouse has gained 
much more popularity.  However, the isolation of AMVMs has proven problematic, 
with non-standardized isolation methods yielding widely differing levels of cell purity 
and stability.  Furthermore, few studies have reported clear cell culture or gene 
delivery protocols for AMVMs, or provided full methods for the functional 
characterization of ion fluxes and calcium transients.  Therefore, in PAPER	 I we 
present detailed methodologies for the isolation, culture, adenoviral transfection, and 
functional analysis of adult mouse ventricular cardiomyocytes.  
7.1.2 Summary of Results 	
The methods presented in this report result in Ca2+-tolerant, excitable adult 
ventricular cardiomyocytes.  The isolated cells maintain the expected rod shape and 
are amenable to electrical field stimulation.  We show that we are able to culture 
them for up to 72 hours and transiently transfect them using an adenovirus 
containing a GFP construct. We further provide detailed methods for contractile and 
Ca2+ transient analysis, whole-cell patch clamp, and present representative graphs 
depicting a typical AMVM AP, calcium transient, and contractility trace. 
 
The basis for this procedure is retrograde perfusion of the adult murine heart ex vivo 
with a specialized enzyme buffer containing collagenases B and D, and protease XIV 
from Streptomyces griseus.  After the mouse is anesthetized, the heart is extracted 
ensuring that the aorta remains visible.  The heart is then mounted onto a 
Langendorff Apparatus by pulling the aorta around a non-hypodermic, blunt end 
needle.  After securing the heart to the needle with a small length of suturing silk, the 
heart is lowered into a temperature-regulated conical glass and perfused first with a 
isotonic perfusion buffer and then with an enzyme buffer.  The heart is perfused for 5 
min at a rate of 1mL/min with perfusion buffer, and then the glass chamber is blocked 
to allow enzyme perfusate to envelop the heart.  As the enzyme perfuses the heart it 
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digests the connective tissue and results in a paler tissue color and decreased tissue 
integrity. After sufficient enzyme perfusion (~7-10 min), the ventricles are cut away 
from the hanging heart, minced, filtered to remove large tissue remnants, and subject 
to calcium equilibration. 
 
The resultant cell suspension can be cultured on glass coverslips that have been pre-
coated with natural mouse laminin.  The desired number of cells are resuspended in 
plating warm media whose dissolved CO2 has been equilibrated to 2%.  The cells are 
allowed to attach for at least 30-60 minutes in an incubator set to 37oC and 2% CO2.  
If adenovirus is to be transfected, the appropriate amount can be added directly to 
the plating media and incubated with the cells for 2 hours.  The plating media is then 
removed and replaced with culture media.  If the media is changed each day the cells 
can be cultured for up to 72 hours using this protocol.   
 
If the aim is to record contractile and calcium transient measurements, we have 
provided a protocol for the use of the MMSYS system.  After proper start-up of the 
system hardware, the system should be primed with calcium buffer.  A coverslip is 
placed in the flow chamber, and this is where the cells are visualized.  Fura2-AM is 
applied to a 500μL aliquot of cell mixture and allowed to incubate at room 
temperature for 5-7 minutes.  An appropriate number of cells are then dropped onto 
the center of the chamber and allowed to settle.  Once settled, the calcium buffer 
flow is initiated and the contractility and calcium transient measurements can be 
taken using the MMSYS software. 
 
Patch clamp recordings are performed using a fire-polished pipette made of 
borosilicate glass.  Cardiomyocytes should be cultured on glass coverslips for this 
procedure, but attachment to collagen- or laminin-coated coverslips will also allow 
the use of fresh cells.  In either case, coverslips are washed with PBS and placed in the 
perfusion chamber of the inverted microscope.  The patch pipette is back-filled with 
intra-cellular buffer and attached to the pipette holder.  The pipette is lowered into 
the cell bath and placed in close proximity to the AMVM.  Mouth pressure is used to 
establish negative pressure on the cell surface to obtain a gigaseal.  Once the gigaseal 
is obtained, the resting membrane potential can be measured using current clamp 
with I=0 pA.  Once whole-cell patch mode is established, 15 minutes of equilibration is 
required before beginning voltage or current clamp protocols.            
7.1.3 Discussion 
 
Though protocols for AMVM isolation have been previously reported, and there exist 
numerous studies using isolated AMVMs as a model system, in many cases the 
technical minutia of the isolation procedure have been left out of the methods 
section.  It is thus of utmost importance that researchers are provided with a 
complete and comprehensive protocol for AMVM isolation, so that healthy cells can 
be obtained reproducibly and to ensure high quality experimentation.  The aim of our 
report was to be as thorough as possible in the description of our isolation, culture, 
and functional characterization methods, to provide investigators with a clear 
procedure that can be followed step-by-step.  We were also interested in describing 
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potential pitfalls of the procedure, in offering cautionary instructions, in providing 
helpful tips based on experience, and in giving examples of common mistakes.  We 
believe that this level of detail should always be provided in any methods paper, to 
ensure that results are reproducible, and to make scientific experimentation more 
effective and efficient.     
 
7.2 PAPER II – Development of dilated cardiomyopathy and impaired 
calcium homeostasis with cardiac-specific deletion of ESRRβ 
7.2.1 Introduction 
 
While many genetic mutations, frequently occurring in the large sarcomeric protein 
titin, have been linked to the development of idiopathic DCM (iDCM), the molecular 
triggers of DCM pathogenesis are still largely unknown.  One important hallmark of 
DCM and heart failure is metabolic dysfunction.  Notably, mutations in vital 
components of mitochondrial function lead to DCM [156-158], highlighting the 
importance of cardiac oxidative metabolism in disease progression.   
 
In PAPER	 II	we performed a gene expression screen in various oxidative tissues and 
cell populations to identify novel transcriptional regulators of cardiac oxidative 
metabolism. We have found estrogen-related receptor β (ESRRβ) to be highly 
expressed in conditions of enhanced metabolic activity, and shown that mice lacking 
cardiac ESRRβ develop DCM in mid-life.  We further show that human heart tissue 
samples from iDCM patients lack nuclear ESRRβ expression, as opposed to samples 
from patients with other forms of cardiomyopathy, suggesting a role for human 
ESRRβ specifically in DCM pathogenesis. 
7.2.2 Summary of Results 
 
Using a high-throughput qPCR screen containing ~2000 transcription factors (TFs), we 
compared the expression of TFs in: (1) slow twitch soleus muscle vs. fast twitch 
quadriceps muscle, (2) quadriceps vs. cardiac muscle, (3) cultured PGC-1α 
overexpressing myotubes vs. GFP-only expressing myotubes, and (4) quadriceps 
muscle from transgenic PGC-1α overexpressing mice vs. littermate controls.  Five TFs 
were significantly enhanced in the more oxidative alternative in all four cases: PGC-1α 
itself, PPARα, FHL2, HMG20b, and ESRRβ.  ESRRβ was the most highly regulated TF 
after PGC-1α, as confirmed by qPCR, and the heart showed the highest ESRRβ 
expression. 
 
A cardiac-specific knockout mouse was generated to determine the role of ESRRβ in 
the heart.  Floxed ESRRβ mice were mated to mice containing an α-MHC driven Cre-
recombinase to create the cardiac-specific ESRRβ knockout mice (MHC-ERRB KO).  
The MHC-ERRB KO mice showed a 95% reduction in cardiac ESRRβ with no loss in the 
skeletal muscle or in the kidneys.  They were born at expected Mendelian ratios, 
exhibited no gross congenital defects, but had poor survival rates after 9-10 months 
of age.  Postmortem analysis of the 9-10 month old hearts revealed significant 
enlargement with increased fibrosis, and qPCR analysis showed an increase in genetic 
markers of heart failure.  Noninvasive echocardiography (ECHO) revealed significant 
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DCM as determined by increased anterior wall thickness, increased LVESD and LVEDD, 
and a 60% decrease in FS.  No evidence of overall cardiac dysfunction was observed at 
earlier time points, but disruptions in contraction occurred at 6 months and, irregular 
calcium handling occurred already at 4 months. 
 
Finally, to test whether or not the subcellular localization of ESRRβ is altered in 
human disease, human heart tissue samples were obtained from patients diagnosed 
with iCM, HCM, iDCM, and ARVC.  Interestingly, nuclear ESRRβ expression was 
completely absent only from the samples from the iDCM patients.  We did not, 
however, observe any significant decrease in ESRRβ mRNA expression, suggesting 
posttranscriptional regulation.  
7.2.3 Discussion 
 
Aside from the electrical and mechanical remodeling that occurs upon the onset of 
heart failure, late-stage heart failure also presents with defects in oxidative 
metabolism.  Because the heart is such a highly metabolic organ, disruption of any 
aspect of the oxidative phosphorylation machinery can lead to cardiomyopathy.  In 
fact, mutations in many vital components of mitochondrial function have been shown 
to lead to DCM [156-158].  In this report we have identified ESRRβ as one such vital 
component, whose absence in the heart leads to late-onset DCM.   
 
Cardiac metabolic function is essential for maintaining the proper contraction of the 
heart.  PGC-1s and many of their downstream effectors, including members of the 
estrogen-related receptor (ESRR) family of orphan receptors, have emerged as vital 
regulators of cardiac metabolism.  The three ESRRs (α, β, and γ) bear significant 
homology to the estrogen receptor, but do not bind estrogen themselves.  While little 
is known about the role of ESRRβ in the heart, ESRRα is considered to be a key 
regulator of mitochondrial biogenesis [159], and germline deletion of ESRRγ results in 
postnatal lethality due to cardiac dysfunction [160].  Germline deletion of ESRRβ is 
also lethal, but lethality occurs already at the embryonic stage due to abnormal 
placental formation [161].  The data presented in this report suggest a role for ESRRβ 
in calcium homeostasis preceding disease onset, but more comprehensive studies will 
be necessary to divine the mechanism by which ESRRβ loss leads to impaired calcium 
handling.        
 
7.3 PAPER III – Pathological Role of Serum- and Glucocorticoid-Regulated 
Kinase 1 in Adverse Ventricular Remodeling 	
7.3.1 Introduction 
 
Heart failure is associated with altered cardiomyocyte electrical characteristics, 
including the prolongation of the action potential duration (APD), which can 
exacerbate the symptoms of adverse mechanical remodeling and even lead to fatal 
arrhythmias.  It has been shown that the persistent (late) sodium current (INa or INaL) 
can contribute to APD prolongation [162], but the mechanisms governing this activity 
are unclear.  It will thus be necessary to fill this knowledge gap to develop a more 
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comprehensive understanding of the electrical and mechanical remodeling 
concomitant with heart failure.   
 
In this context, serum- and glucocorticoid-regulated kinase 1 (SGK1) is of particular 
interest.  SGK1 is a member of the serine/threonine family of kinases, is involved in 
the phosphatidylinositol 3-kinase (PI3K) signaling pathway, and has been shown to 
regulate sodium ion transport in the kidney [163, 164] and in other heterologous 
expression systems [165].  The PI3K signaling pathway has been shown to promote 
cardiomyocyte survival, but proximal PI3K signaling is also enhanced in patients with 
cardiac dysfunction and heart failure.  This paradoxical activity of the PI3K signaling 
pathway has raised the possibility that, while its acute activation is initially 
cardioprotective, prolonged activation may become maladaptive and contribute to 
the adverse ventricular remodeling commonly associated with heart failure.  Acute 
activation of SGK1 has been shown to promote cardiomyocyte survival after TAC in 
mice.  However, in PAPER	 III we have demonstrated that SGK1 is also persistently 
activated after TAC as well as in human heart disease.  We show that chronic 
activation induces hallmarks of both adverse mechanical and electrical remodeling, 
echoing previous reports describing cardiac dysfunction upon sustained PI3K 
signaling.  Based on these findings, we expect that inhibition of chronic SGK1 
activation may provide a novel avenue for heart failure treatment, especially in 
patients with a history of cardiac arrhythmia.  Indeed, aspects of adverse remodeling 
could be reversed with treatment of the late sodium current inhibitor, ranolazine.        
7.3.2 Summary of Results 	
In this report we show that cardiac SGK1 remains elevated in TAC heart failure 
models.  We did not, however, observe any changes in phosphorylated (pSGK1) or 
total SGK1 levels in an exercise model of physiological hypertrophy, suggesting that 
the observed elevation of SGK1 levels corresponds to pathological remodeling.  Total 
SGK1 levels were also elevated in human heart tissue samples from patients with 
hypertensive heart disease, and pSGK1 levels were increased in DCM samples with no 
change in total SGK1. 
 
The functional role of SGK1 in the heart was tested using transgenic mouse lines with 
cardiac-specific expression of either a constitutively active or dominant negative form 
of SGK1 (SGK1-CA, SGK1-DN).  The baseline SGK1 kinase activity of the SGK1-CA mice 
was comparable to that seen in the hearts of mice with TAC-induced heart failure 
(TAC-HF), and the baseline kinase activity in the SGK-DN mice was no different than 
that seen in WT littermates. However, after TAC, the rise in SGK1 activity seen in the 
WT mice was absent in the SGK1-DN mice.  No gross changes in cardiac structure 
were observed in young adult mice (3-6 months) of either genotype, but SGK1-CA 
mice presented with mild, but significant, systolic and diastolic dysfunction.   
 
When these mice were subjected to TAC, there was a significant increase in the heart-
weight-to-body-weight ratio (HW/BW) in both the SGK1-CA mice and WT littermates, 
but the SGK1-CA hearts were dilated, had thinner walls, and exhibited reduced 
cardiac functionality.  The SGK1-DN mice tolerated the TAC to a similar extent as the 
WT mice, though the HW/BW was less pronounced in the SGK1-DN seven weeks after 
		 45	
TAC.  Furthermore, also after seven weeks, ECHO revealed decreased FS and 
increased LV dilation in the WT but not in the SGK1-DN hearts.  SGK1-DN mice also 
showed less fibrosis than WT littermates.       
 
Because SGK1 is known to interact with ion channels, we next investigated the 
electrophysiological effects of chronic SGK1 activation.  SGK1-CA mice showed 
increased R-wave amplitude, QRS duration, and QTc interval, with no change in RR or 
PR intervals.  Ventricular tachycardia was also reported at 12-months.  SGK1-DN ECGs 
were no different from WT mice, and no ventricular arrhythmias were observed.  
Whole-cell patch clamp of SGK1-CA cardiomyocytes from young adult mice showed 
AP prolongation as compared to WT littermates.  Early and delayed after-
depolarizations were also more frequent in SGK1-CA mice. 
 
Based on the reasoning that prolonged APD is likely secondary to alterations in the 
peak calcium, potassium, or sodium currents (ICa, Ito, IK1, or INa) we next performed 
whole-cell patch clamp on isolated cardiomyocytes from SGK1-CA mice or WT 
littermates to investigate ion current densities.  We found no changes in Ito, IK1, ICa, 
but observed substantial changes in INa.  SGK1-CA mice exhibited a 3.6-fold increase in 
the persistent sodium current INaL compared to WT littermates, which is comparable 
to that seen in arrhythmogenic SCN5a mutations or in acquired HF [166, 167]. 
Blocking INaL with low concentrations of ranolazine normalized APD in SGK1-CA 
without affecting WT APD, and reduced the number of SGK1-CA cardiomyocytes with 
after-depolarizations.  Furthermore, in vivo ranolazine treatment of SGK1-CA mice 
reduced the incidence of lethal ventricular arrhythmias after I/R injury, and showed a 
trend towards improved FS, with no difference in placebo-treated animals. 
 
In order to understand the molecular basis for the changes in INa, we next explored 
the effects of SGK1-CA on Nav1.5, the primary pore-forming subunit of the cardiac 
voltage-gated sodium channel complex.  While there were no changes in total Nav1.5 
protein expression in the SGK1-CA or SGK1-DN mice, the subcellular localization of 
Nav1.5 was altered in both TAC-HF as well as in SGK1-CA mice, but not in sham-
operated WT or TAC’d SGK1-DN mice.  In sham-operated WT mice most of the Nav1.5 
was localized to lipid rafts, with small amounts localized to the heavy membrane (HM) 
fraction.  Conversely, TAC-HF and SGK1-CA hearts both showed increases in Nav1.5 in 
the HM fraction.  Of note, the amount of HM Nav1.5 was markedly decreased in 
SGK1-DN mice following TAC as compared to TAC’d WT littermates.  We also found 
that the increased HM Nav1.5 was consistent with increased membrane availability 
due to decreased binding to Nedd4-2.  Nedd4-2 is a ubiquitin ligase that has been 
shown to bind and decrease the surface expression of the epithelial sodium channel 
ENaC in renal tubular cells in response to SGK1 activation [163].  Nedd4-2 binding was 
preserved in SGK1-DN mice after TAC.   
 
The altered binding to Nedd4-2 could potentially explain the global increases in INa, 
but not the changes in channel gating and kinetics.  To investigate alternative 
contributors, we also tested whether or not SGK1 interacts directly with Nav1.5.  
Immunoprecipitation assays revealed that endogenous SGK1 does bind to cardiac 
sodium channels, but perhaps not only to Nav1.5.  However, using a peptide library, 
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we determined the preferred SGK1 phosphorylation target and have identified 
putative consensus sites on the SCN5a gene, suggesting a physical role for SGK1 in 
Nav1.5 regulation.    
7.3.3 Discussion 	
It has been established that proximal PI3K activation is maladaptive in heart failure, 
and here we present chronic activation of SGK1 as a vital player in the associated 
electrical remodeling.  By demonstrating its effect on the subcellular localization of 
the primary cardiac voltage-gated sodium channel, Nav1.5, we have shown that SGK1 
activation is necessary for at least some of the aspects of adverse electrical 
remodeling.  Other kinases are also potent modulators of Nav1.5 [168-170], so the 
singular inhibition of SGK1 may not be sufficient to fully protect against heart failure 
phenotypes.  We were, however, able to block the biochemical changes caused by 
constitutive SGK1 activation by using a dominant negative SGK1 mouse model and 
also by abrogating INaL with ranolazine.  Further studies will be necessary to determine 
to what extent SGK1 contributes to electrical remodeling when considering other 
Nav1.5 regulatory elements, and a deeper understanding of the physiological 
degradation of SGK1 via the 26S proteasome [171] in the cardiac milieu may also 
elucidate novel therapeutic strategies. 
 
Our report of putative SGK1 phosphorylation sites on SCN5a also begs further 
investigation.  Previous studies have shown that mutations of human SCN5a can lead 
to both arrhythmia and cardiomyopathy, so the direct Nav1.5 phosphorylation by 
SGK1 could provide a mechanistic link between the PI3K signaling pathway, heart 
failure, and ventricular arrhythmia, especially considering that one of the candidate 
SGK1 phosphorylation targets resides in a region known to be important in channel 
inactivation gating [172].           
 
In sum, this study highlights the importance of SGK1 activation in heart failure 
pathogenesis and concomitant arrhythmogenesis.  It cannot be concluded that SGK1 
is the sole player in the observed adverse electrical remodeling, but inhibition of 
chronic SGK1 in heart failure could prove salutary and certainly warrants further 
investigation.   	
7.4 PAPER IV – Exploring distinct gene expression profiles in zebrafish 
models of cardiac regeneration 
7.4.1 Introduction 
 
In mammals, the cardiomyocytes lost as a result of myocardial infarction are replaced 
by inflexible scar tissue, severely hampering cardiac functionality.  Cardiac 
regeneration has been observed in neonatal mammals and in various non-mammalian 
vertebrates [101, 102, 120, 173], but a comprehensive understanding of the 
molecular drivers of this regenerative capacity is still lacking.  For example, the 
neonatal mouse has demonstrated a seven-day postnatal regenerative window [120], 
urodele amphibians have shown complete cardiac regeneration after both apical and 
basal resection [104], and approximately 20% of the ventricular myocardium can be 
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removed from the apex of the adult zebrafish heart with no discernable dysfunction 
after 60 days of recovery [107].   
 
In order to understand the mechanisms governing the initiation of this remarkable 
regenerative capacity in the zebrafish, in PAPER	 IV we have employed a genetic 
cardiomyocyte ablation (GA) model of cardiac regeneration in conjunction with 
microarray analysis to identify key regulatory signaling pathways and molecular 
drivers of cardiomyocyte proliferation.  We compared the transcription profile from 
our genetic injury model to models of apical resection and cryoinjury in an attempt to 
identify a core regulatory gene set and to determine the level of genetic discrepancy 
between the three different models of zebrafish cardiac regeneration. 	
7.4.2 Summary of Results 	
To elicit a regenerative response, we made use of the NTR/MTZ system.  In the 
absence of NTR, the MTZ is a benign substance.  When exposed to NTR, MTZ is 
reduced to a DNA chelating agent, causing apoptosis of the cell expressing NTR [174].  
Zebrafish expressing an mCherry-NTR fusion protein specifically in cardiomyocytes 
were exposed to 5mM MTZ for 2 hours resulting in a significant increase in 
cardiomyocyte proliferation, as measured by phospho-histone H3 (PH3) positivity, 
after 4 days of recovery.   
 
Total mRNA from whole hearts of MTZ treated fish was then analyzed by microarray, 
and clustering analysis showed an intense and consistent gene activation profile.  In 
all, 135 genes were found to be significantly up-regulated after injury and 46 genes 
were significantly down-regulated.  Gene ontology (GO) analysis indicated an 
enrichment in biological pathways associated with cell-cycle and mitosis, amino acid 
biosynthesis and metabolism, folate metabolism, organic molecule ion transport, and 
cytoskeletal organization.  Protein modification/ubiquitination, external stimulus 
response, and cell signaling were the most significantly enriched biological processes 
associated with the down-regulated genes.   
 
When the transcriptional profile from our screen was compared with two models of 
apical resection (AR) and one model of cryoablation (CA), we found 16 genes to be 
commonly up-regulated in all screens, and one gene commonly down-regulated.  A 
subset of these genes have been directly associated with the cell cycle, supporting the 
current hypothesis that zebrafish heart regeneration is driven primarily by 
cardiomyocyte proliferation.  Furthermore, GO analysis of the 16 up-regulated genes 
revealed mitotic cell cycle activity as the most significant biological process associated 
with this gene set.  The common down-regulated gene, Cited4a, has not been 
explored in the context of zebrafish regeneration, but has been shown to be 
cardioprotective in mice after ischemic injury [175].       
 
We were also interested in understanding the interactions between the commonly 
regulated genes.  To that end, we used the Ingenuity Pathway Analysis software to 
explore previously described interrelations and cellular localizations.  Interestingly, 
the genes primarily associated with the cell cycle all coded for nuclear proteins, and 
were predicted to create an interconnected network therein.  We were also able to 
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use this tool to predict potential transcriptional and miRNA regulators, most of which 
have been reported previously to interact with the cell cycle-related proteins.  
 
Interestingly, analysis of the comparisons also revealed large discrepancies in gene 
expression between the various models.  The two AR screens and the CA screen 
showed 59, 222, and 1315 model-specific up-regulated genes, respectively, while 82 
genes were specifically up-regulated in our GA model.  When considering the down-
regulated genes, 74, 257, and 464 genes were observed respectively in the two AR 
screens and the CA screens.  Thirty-four genes were down-regulated in the our GA 
model.  To determine the specific biological processes associated with each model 
system, we also performed GO analysis on the model-specific up- and down-
regulated genes and observed distinct ontology for each injury model.  This suggests 
that the regenerative responses resulting from the disease paradigms may also be 
genetically distinct.       
7.4.3 Discussion 	
In the current study we have identified 17 commonly regulated genes in four 
different transcriptional studies of zebrafish heart regeneration comprising three 
different injury model systems.  We suggest that these genes comprise, at least in 
part, a core gene set necessary for complete cardiac regeneration regardless of injury 
methodology.  We further present potential upstream regulators of these genes, so 
as to build a more comprehensive overview of the regenerative pathways at play 
after cardiac injury in the zebrafish.  Future studies should focus on the validation of 
these potential signaling pathways, and on investigating the commonly up- and down-
regulated genes in gain- and loss-of-function studies. 
 
Our report of the model-specific regulated genes also begs further investigation.  It is 
perhaps not surprising that different injury models lead to different regenerative 
responses, but the data presented here suggest that the regenerative response is not 
simply a function of injury severity, but that different injury paradigms may lead to 
genetically distinct regenerative avenues.  In this way, these disease paradigms should 
not be used as interchangeable models of cardiac regeneration, but should be 
individually characterized to determine their complete pathophysiology, as the 
regenerative responses may be tailored accordingly.  
 
7.5 PAPER V – Regeneration of human cardiomyocytes in cardiomyopathy 	
7.5.1 Introduction 
 
There is an emerging consensus that human cardiomyocytes do have a limited 
proliferative capacity that extends even into adulthood.  We have previously shown 
that cardiomyocytes in the healthy human heart are able to renew to a limited extent 
for the lifetime of the individual [136, 138, 176].  In fact, we have found that almost 
40% of the ventricular myocytes present at birth will be exchanged during a normal 
lifetime.  However, whether or not this innate regenerative capacity is utilized after 
cardiac injury is still controversia
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reported cardiomyocyte division in end stage heart failure, but these studies may be 
confounded by the propensity of cardiomyocytes to polyploidize and/or 
multinucleate as a result of disease onset [126].   
 
In order to provide a more holistic view of the magnitude and dynamics of cardiac cell 
turnover in the pathological human heart in PAPER	V	we have made use of 14C-dating 
of postmortem cardiac tissue from patients diagnosed with dilated cardiomyopathy.	
7.5.2 Summary of Results 
 
In this report we analyzed heart samples from 15 DCM patients aged 17 to 65 years 
using retrospective 14C birth dating to establish the age and turnover dynamics of 
cardiomyoctyes in dilated cardiomyopathy.  Disease onset was assumed to be 
consistent with the time of diagnosis.  Cardiomyocyte nuclear 14C levels were 
measured using accelerator mass spectrometry, and cardiomyocyte nuclei were 
identified and isolated based on positive immunostaining for the perinuclear protein 
PCM-1.  Ploidy levels were determined by nuclear DNA staining and fluorescence 
activated cell sorting.   
 
Ploidy analysis revealed higher ploidy levels in DCM as compared to healthy control 
samples.  This increased ploidy resulted in a total increase in cardiomyocyte DNA from 
180.2% ± 13.1% in healthy subjects to 337.9% ± 108.7% in DCM (2n baseline = 100%).  
However, we did not detect a significant increase in the number of binucleated 
cardiomyocytes, suggesting that the increase in DNA content with disease is not due 
to binucleation.  
 
The 14C data obtained from the cardiomyocytes of DCM patients followed the 
atmospheric bomb curve to a less extent than the data from healthy samples, 
indicating increased DNA synthesis in pathological cardiomyocytes.  While ploidy does 
explain a large portion of the 14C integration in cardiomyocyte nuclear DNA of DCM 
patients, it could not explain the 14C data entirely.  To develop a model fitting the 
observed data, we tested three different polyploidization scenarios. The ploidy levels 
of both the healthy and DCM samples showed significant differences from the 
measured 14C values in all cases, and none could be explained by polyploidization 
alone.  Our mathematical model predicts that cardiomyocyte turnover is at least 
maintained in DCM, and that the turnover rate might be increased in DCM as 
compared with healthy individuals. 
 
From these findings, we were able to continue data analysis under the condition of 
non-zero turnover with pathology.  To address the question of renewal after disease 
onset, we assumed a constant rate of cardiomyocyte turnover before disease onset, 
and a different (constant) rate of renewal after onset.  Comparing this model to the 
restricted, no-renewal model, we found that the data were best described by 
constant renewal after disease onset.  This model suggests that the decreased 
cardiomyocyte turnover occurring before disease onset is compensated afterwards by 
higher turnover.  However, increased post-onset turnover was not able to explain the 
data better than the restricted model, holding a constant, lifelong turnover rate.            
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Using similar 14C dating methods we were also able to determine the turnover rates 
of non-cardiomyocyte populations in healthy and DCM subjects.  Our model predicted 
a turnover rate of 5.9% per year in healthy subjects and 11.1% per year in DCM.  This 
seemingly marked increase did not reach statistical significance, but we did detect an 
unexpected population of non-cardiomyocytes (~10% of the total complement) 
exhibiting no or low turnover rates.  Further studies will be necessary to determine 
the identity of this cell population and its role in cardiac pathophysiology.    
7.5.3 Discussion 	
In this investigation, we have used 14C dating to determine the magnitude and 
dynamics of cardiomyocyte and non-cardiomyocyte renewal in dilated 
cardiomyopathy.  While non-cardiomyocyte renewal rates were not significantly 
different between healthy and diseased individuals, the rate of cardiomyocyte 
renewal increased after the onset of DCM.  Based on our model, we have found that 
cardiomyocytes corresponding to 2.3 – 3.3% of the full complement are generated 
per year after diagnosis.  That is to say that in a patient with a ten-year history of 
DCM, ~28% of their existing cardiomyocytes will have been exchanged.  However, 
though the rate of cardiomyocyte renewal is significantly increased after the onset of 
disease, using our model, we are not able to determine whether or not the increased 
cardiomyocyte generation is a result of an increased turnover rate after disease 
onset, or if it is due to a constant, lifelong turnover.  In any case, all the DCM patients 
studied had clear evidence of reduced cardiac function, indicating that the 
augmented renewal was not sufficient to completely compensate for the pathological 
changes.  It cannot be discounted that the new cardiomyocytes contributed to patient 
survivability, but further studies will be necessary to determine whether the 
prolonged disease duration resulted in increased cardiomyocyte renewal or if the 
increased cardiomyocyte renewal resulted in longer life. 
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